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VACCINIA VIRUS BINDING AND INFECTION OF PRIMARY HUMAN B CELLS 
 
Vaccinia virus (VACV), the prototypical poxvirus, was used to eradicate 
smallpox worldwide and, in recent years, has received considerable attention as 
a vector for the development of vaccines against infectious diseases and 
oncolytic virus therapy. Studies have demonstrated that VACV exhibits an 
extremely strong bias for binding to and infection of primary human antigen-
presenting cells (APCs) including monocytes, macrophages, and dendritic cells. 
However, very few studies have evaluated VACV binding to and infection of 
primary human B cells, a main type of professional APC. In this study, we 
evaluated the susceptibility of primary human peripheral B cells at different 
developmental stages to VACV binding, infection, and replication. We found that 
VACV exhibited strong binding but little entry into ex vivo B cells. Phenotypic 
analysis of B cells revealed that plasmablasts were the only subset resistant to 
VACV binding. Infection studies showed that plasma and mature-naïve B cells 
were resistant to VACV infection, while memory B cells were preferentially 
infected. Additionally, VACV infection was increased in larger and proliferative B 
cells suggesting a bias of VACV infection towards specific stages of 
differentiation and proliferative ability. VACV infection in B cells was abortive, and 
cessation of VACV infection was determined to occur at the stage of late viral 
gene expression. Interestingly, B cell function, measured by cytokine production, 
was not affected within 24 hours post-infection. In contrast to ex vivo B cells, 
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stimulated B cells were permissive to productive VACV infection. These results 
demonstrate the value of B cells as a tool to aid in deciphering the intricacies of 
poxvirus infection in humans. Understanding VACV infection in primary human B 
cells at various stages of differentiation and maturation is important for the 
development of a safer smallpox vaccine and better vectors for vaccines against 
cancers and other infectious diseases.    
Andy Qigui Yu, Ph.D., Chair  
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Chapter I - Introduction 
 
Virus Tropism 
 In spite of the advancement in preventing and treating infectious diseases, 
there are many emerging and re-emerging pathogens, of which the majority are 
viruses. The multitude of emerging and re-emerging viruses include Filoviruses 
(Ebola and Marburg), Flaviviruses (hepatitis C, Dengue, and Zika), 
Coronaviruses (MERS-CoV), Bunyaviruses (hantavirus), Retroviruses (HIV-1), 
and Poxviruses (monkeypox) (1). Despite the advances in science, medicine, 
and technology, intervention to control viral diseases mostly depends on 
vaccines, novel medical practices, and antivirals. Antiviral drug development has 
progressed relatively slower when compared to that of antibiotics. Regardless of 
these advances, emerging and re-emerging pathogens remain as a primary 
concern for global healthcare (1). Emergence of a virus as a causative agent of 
human disease may occur by zoonosis, transfer of disease from another species 
to humans, which is limited by host tropism.  
 Viral tropism determines the permissiveness of a species to a virus and 
can be viewed and described from a microscopic to macroscopic level. Tropism 
is a tri-leveled barrier system involving cellular, tissue, and host specificities (2). 
All three levels of viral tropism are very interdependent; however, each level has 
unique features that interact to regulate the virus-host interactions thus regulating 
specificity. Host tropism, which is largely affected by cellular and tissue tropism, 
is organism specificity and defines whether the whole species supports either 
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abortive or permissive viral infections. Variola virus (VARV), the causative agent 
of smallpox, infection demonstrates an example of host tropism because of its 
human-specificity and lack of natural reservoir. Tropism is defined by the 
symptoms of disease, possible range of effects from viral pathogenesis, and the 
ability to infect other individuals. Certain hosts or organisms with no overt 
disease can be a reservoir and can still infect other individuals or species.  
The second level of viral tropism is tissue specificity which influences 
organism tropism and is influenced by cellular tropism. This level of specificity is 
determined by tissue-specific antiviral responses and largely dependent on the 
patterns of virus distribution and dissemination within the host. It also affects the 
ability of the virus to spread between hosts (2). For example, hepatitis B virus 
infection is strictly species and tissue specific, as humans are the only natural 
hosts of hepatitis B virus infection, and the liver is the only tissue where viral 
replication takes place. 
 The final and microscopic level is cellular specificity. On a cellular level, 
virus replication for certain cell types of specific species can either be permissive 
or abortive (2). Permissive infection is represented by success in entering and 
replicating in the cell. Obligate intracellular pathogens, such as viruses and 
bacteria, require specific host factors on the cell surface and in the cytoplasm, to 
gain entry into a cell, replicate, and disseminate to other cells. Viruses must bind 
to their receptors on the target cell’s surface to initiate or induce entry of the virus 
particle either by a form of endocytosis or membrane fusion, depending on the 
pH, virus, and other various factors. Abortive infections are often the result of 
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disruptions in virus replication. Interspecies and intercellular barriers, such as 
intracellular factors and disruptions in virus-receptor interactions, can contribute 
to non-productive viral infections. HIV-1 demonstrates an example of cellular 
tropism by exclusively entering and productively infecting cells expressing CD4 
and CXCR4 or CCR5.  
  
Poxvirus tropism 
 Poxviruses are a family of complex, large, enveloped DNA viruses with a 
wide range of species specificities. The brick-shaped sub-family 
Chordopoxvirinae specifically infects vertebrates and includes four genera that 
contain viruses that can infect humans. These four genera are yatapoxvirus, 
molluscipoxvirus, parapoxvirus, and orthopoxviridae. Orthopoxviruses are 
mammal specific, morphologically indistinguishable, replicate exclusively in the 
cytoplasm, and have approximately 250 genes. This genus includes Variola 
major, camelpox, monkeypox, cowpox, and vaccinia. 
 Variola virus, the causative agent of smallpox, was a tremendously deadly 
virus that killed hundreds of millions of people and is likely the deadliest 
pathogen in history (2). The first vaccine was discovered by Edward Jenner in 
the late 1700’s and developed against VARV. The initial smallpox vaccine was 
live cowpox virus which provided cross protection against smallpox, among many 
of the Orthopoxviruses, due to the extreme sequence similarity and relatively 
slow rate of mutation of poxviruses (3, 4). Over the years, the smallpox vaccine 
was altered to increase the safety by now using a live, attenuated vaccinia virus 
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(VACV), the prototypical poxvirus. Attenuation of VACV provided a near certainty 
of developing an acquired immunity against smallpox with relatively benign 
symptoms following percutaneous inoculation and infection. The development of 
the attenuated VACV vaccine allowed for a global smallpox eradication campaign 
in 1967 which lead to the complete eradication of smallpox by 1979 (5).  
While smallpox has been eradicated, various poxviruses are emerging as 
primary concerns for global healthcare, such as molluscum contagiosum, 
cowpox, and monkeypox (6-12). These emerging poxviruses are causing natural 
infections in several countries and can lead to mortality in certain cases of 
monkeypox (6-8, 12). Additionally, smallpox still remains a threat as a 
bioterrorism agent due to the unaccounted-for stocks of VARV in 
decommissioned labs and vast majority of the population lacking vaccination with 
VACV (13). 
 For poxviruses, failure or success at the various stages of the viral life 
cycle determines cellular tropism. Orthopoxviruses first bind to host receptors 
and can enter into a cell by one of two ways. Poxviruses enter by membrane 
fusion at the cell surface at a neutral pH, while entry at a low pH follows an 
endocytic pathway with virus fusion inside the vesicle membrane. The viral 
capsid then uncoats by degradation and early genes encoding factors necessary 
for viral DNA replication and immunomodulation are transcribed (Fig.1). VACV 
DNA replication occurs exclusively in a cytoplasmic endoplasmic reticulum (ER)-
enclosed mini-nucleus (14). These mini-nuclei, also known as viral replication 
factories, are comprised of a section of the rough ER organized to allow for 
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assembly of viral particles. After viral DNA replication, two more waves, 
intermediate and late, of viral mRNA and protein synthesis occurs before 
subsequent morphogenesis of infectious particles. These infectious viral particles 
exit the viral replication factory as intracellular mature virions (IMV), one of two 
distinct infectious virus particle types, that are transported along microtubules 
(15). IMVs exist as single enveloped virions in the cytoplasm; however, some 
IMVs are transported to the Golgi apparatus where they are wrapped in a double 
membrane derived from the Golgi and referred to as triple-enveloped intracellular 
enveloped virus (IEV) (15). IEVs are then transported once more along 
microtubules to the surface to fuse with the plasma membrane to release cell-
associated enveloped virus (CEV) from the cell. CEVs, double membraned 
virions, either stay associated with the cell surface or are released as the other 
type of infectious virus particle known as extracellular enveloped virus (EEV). 
CEVs are released by various mechanisms, and commonly launched from the 
surface to neighboring cells via intracellular actin polymerization. Additionally, 
IMVs can bypass the IEV form and directly bud from the cell to form EEVs (16-
18).  
 On a cellular level, several restriction events involving regulatory factors 
that control key intracellular steps have been discovered to control poxvirus 
infection. Four main regulating events are signal transduction, cell lineage and 
differentiation state, cell cycle control, and complementing host factors. Signal 
transduction focuses on the various signaling pathways involved in coordinating 
the cellular response to viral infection (2). The antiviral responses are one of the 
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most studied examples of this event, and the interferon (IFN) response is key to 
controlling poxvirus infections. Poxviruses employ several strategies to inhibit the 
IFN response, which include receptor mimics, phosphatases to block signal 
transduction, and inhibitors of IFN induction and mediators (2). Infection by some 
poxviruses has been shown to be dependent on the differentiation state of the 
host cell potentially due to the cellular factors required for viral replication (2). 
Although poxviruses are less S-phase-dependent than most other viruses, they 
secrete homologues to growth factors responsible for stimulating mitosis to 
control the cell cycle (2). The final event regulating poxvirus replication is the 
necessity for hijacking trans-acting factors to complete viral replication (2). One 
example is molecule chaperone Hsp90 that regulates viral replication (19). 
Failure of poxviruses to employ these strategies leads to the antiviral response 
aborting or halting the infection.  
 Another key factor in poxvirus tropism is the viral host-range genes, which 
is important despite highly similar genomes between poxviruses. These host-
range genes, divergent between the poxviruses, are essential for allowing 
poxviruses to specifically infect and thrive in certain species, thus leading to 
restriction in host tropism. Myxoma virus causes lethal disease specifically in 
rabbits only (20), while VARV expresses host-range genes leading to strict 
human-specific infection (2). The first host-range genes, K1L and C7L, were 
identified in VACV (21, 22). The inability of VACV to infect Chinese hamster 
ovary cells has been shown to be rescued by cowpox virus gene CP77, which 
compensated for K1L and C7L in a restrictive host cell (23). While many host-
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range genes have been discovered, K3L and E3L are the best characterized 
genes in VACV. The genes prevent PKR from activating the IFN response and 
inducing apoptosis. Poxvirus infections, among other viral infections, produce 
double-stranded RNA (dsRNA) that is detected by the host cell leading to the 
initiation of innate immunity. PKR is responsible for detecting dsRNA in humans. 
VACV has evolved to utilize two strategies to circumvent detection of dsRNA by 
PKR. One strategy, involving K3L, is to encode a decoy PKR or pseudo-
substrate to avoid discovery and inhibit PKR by mimicking eIF2α (24). The other 
strategy is to disguise the RNA with E3L by binding to dsRNA and sequestering it 
from PKR and other pattern recognition receptors to prevent activation (24). 
Reduced rates of infectivity have been noted when K3L and E3L were deleted in 
VACV (24).   
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Figure 1. VACV life cycle. Overview of the VACV progression of infection from 
McFadden G. 2005. Poxvirus tropism. Nat Rev Microbiol 3:201-213. 
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Poxvirus binding and entry 
 Virus binding often begins with largely non-specific and electrostatic 
interactions between viral surface components and host cell surface factors such 
as glycolipids and glycoprotein attachment factors. These initial interactions 
provide an initial attachment to the host cell which allows the virus to 
subsequently recruit specific receptors to drive the entry reactions. After binding 
to their receptors, viruses need to induce entry of viral particles by either a form 
of endocytosis or membrane fusion. Receptors can either efficiently target the 
viruses for endocytosis or be used to activate specific signaling pathways to 
facilitate entry or drive fusion/penetration events. These signaling pathways can 
also be used to elicit fusion/penetration not only at the host cell surface level but 
also be involved in altering the endocytic compartments by inducing 
conformational changes in virus surface structures. This pH-independent route 
involves capsid degradation to uncoat the virus. The virus capsid degrades once 
the virus has entered the host cell cytoplasm in the presence of specific 
intracellular host factors. The use of specific host cell surface components with 
restricted expression patterns is one form of viral tropism. Membrane fusion often 
occurs in a pH-dependent manner via the induction of lower pH environments as 
with virus containing endosomes which are endocytosed.  
 Although advances in understanding poxvirus cellular tropism has 
occurred using cell lines, no specific cellular receptor for any poxvirus had yet 
been identified for cell lines or primary cells. Several ubiquitous carbohydrate-
based molecules have been suggested as receptors for VACV; however, these 
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molecules have been recently shown to be involved in the first interactions 
needed between virus and host cell to drive receptor binding. The first of these 
discovered were heparin sulfate (HS) and chondroitin sulfate (CS), which are 
highly negatively charged, complex, unbranched polysaccharides called 
glycosaminoglycans (GAGs) that are associated with numerous membrane 
proteins (25). Two VACV envelope proteins, A27 and H3, have been reported to 
bind HS and VACV D8 protein binds to CS (26-29). An additional VACV protein, 
A26, has been shown to bind to extracellular matrix laminins, which are 
complexes of glycoproteins with multiple functional isotypes (30). Soluble HS as 
well as soluble A27, H3, and D8 are able to reduce VACV attachment and 
infection suggesting that GAGs play an important role in virus infection at the 
attachment and binding stage. Additionally, GAG deficit cells are more resistant 
to VACV binding (31). Thus, GAGs are important to VACV binding, providing the 
initial interaction between host cell and VACV, but are not essential to VACV 
infection. In addition to the GAG-dependent VACV binding, GAG-independent 
binding has been noted in GAG-deficient cells and was pinpointed to the 
involvement of L1. A soluble, truncated L1 was shown to bind to GAG-deficient 
cells and lead to inhibition of binding and entry (32). Although VACV has 
redundancies for most processes including binding and entry, VACV has a 
strictly sequential, temporal viral gene expression process.   
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Poxvirus Gene Expression 
 Among the various natural occurring viruses, viral gene expression can 
vary between a simpler system of regulation to a more complex form of 
regulation. Viral transcription is usually controlled by interactions between pre-
existing cellular transcription factors and virally encoded transcription factors and 
regulatory proteins. These interactions can in part be regulated by the cellular 
factors present in certain cell types and can drive the outcome of infection in the 
host cell (33). Importantly, these virus-host transcriptional regulatory interactions 
are fundamental to the permissivity of infection. Simple viral gene expression, 
often seen in smaller viruses such as polyomaviruses and papillomaviruses, 
tends to occur in two defined stages with the necessity of early gene expression 
for subsequent late gene expression (33). Additionally, simple viral gene 
expression is usually regulated by the host cell type due to greater dependence 
on host factors for replication (33). Larger viruses, like herpesviruses and 
adenoviruses, tend to have more complex gene expression with additional 
temporal phases compared to smaller viruses. These viruses are also affected by 
the cell type and supplementary regulatory protein encoded genes (33). 
Since poxviruses replicate in the cytoplasm compared to most viruses that 
replicate in the nucleus, poxviruses encode most of their own transcription and 
replication factors to regulate viral gene expression. VACV contains 
approximately 250 genes, which are involved in regulating gene expression or 
regulated by viral gene expression, that can be classified temporally as early, 
intermediate, or late (34). However, these genes are not exclusively expressed 
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during these times, i.e. intermediate genes can also be expressed during the late 
gene phase and thus having a dual promoter (35). Transcription in VACV, as well 
as other Orthopoxviruses, is mediated by a multi-subunit DNA-dependent RNA 
polymerase along with temporal stage-specific transcription factors that 
recognize affiliated promoters (36). 
Poxvirus early genes encode proteins involved in intermediate gene 
expression (37), DNA replication (38), and nucleotide biosynthesis (39). Host 
defense evasion genes are also included in the early genes (40, 41). These 
genes are transcribed with the assistance of RNA synthesis machinery packaged 
within the core of new infectious virus particles (42-44). Early transcription occurs 
within minutes of infection, before the viral core loses considerable structural 
integrity (45, 46). This data suggests that VACV early transcription involves no 
host factors and is exclusively performed by viral proteins (47). Intermediate and 
late viral genes are transcribed following DNA replication and occurs in the 
cytoplasm outside of the viral core. Since intermediate and late gene expression 
occur in the cytoplasm, specific cellular factors, such as G3BP, p137, TATA-
binding protein, and YY1, have been reported to participate in intermediate and 
late gene expression (48-52). Genes of the intermediate stage encode 
transcription factors for late gene expression. Intermediate genes G8R, A1L, and 
A2L encode proteins required for late gene transcription (53-55). Finally, late 
genes encode structural proteins and necessary proteins for transcription of early 
genes. Viral gene expression has been shown to play an important role in 
abortive poxvirus infections (56). 
13 
Abortive poxvirus infection in primary human leukocytes  
Poxviruses infect a wide range of organs, tissues, and cell types; however, 
the infection can be abortive, the termination of infection due to various factors, 
or productive, the generation of new progeny. VACV is among the most 
promiscuous poxviruses, as it is able to infect the majority of cell lines. Some of 
these cell lines are infected, but result in abortive infection, such as Chinese 
hamster ovary (CHO) cells and certain B lymphocyte cell lines. The abortive 
VACV infection in CHO cells was shown to occur at the stage of intermediate 
viral protein synthesis (57). B lymphocyte cell lines demonstrate differences in 
permissivity of VACV infection depending on the stage of differentiation (58, 59). 
Although VACV displays promiscuous infection in cell lines, infection in primary 
human cells has been shown to be a different case (56, 60, 61). Monocytes and 
B cells are able to be infected by VACV, but resting T cells display resistance to 
VACV infection (61). Upon activation of T cells, T cells exhibit a loss of resistance 
and a gain of susceptibility to VACV infection and permissive infection (56). 
Additionally, dendritic cells and macrophages are susceptible to VACV infection. 
Antigen presenting cells (APCs) including monocytes, dendritic cells, and B cells 
are preferentially infected, but the majority result in abortive infection (56, 62). 
Infection in primary monocytes and B cells displayed abortive infection during the 
viral gene expression stage (56). While VACV infection has been thoroughly 
described in most primary APCs, the pathway for B cell infection by VACV 
remains less clear.  
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VACV infection in B lymphocyte cell lines and primary B cells 
 Few studies have focused on VACV infection in B cells, whether it be in 
cell lines or primary human B cells. The majority of B cell-VACV interaction 
studies have been completed using either peripheral blood mononuclear cells 
(PBMCs) or various B lymphocyte cell lines. VACV infection studies in PBMCs 
have found that B cells display strong VACV binding but minimal infection (60, 
61), and the infected cells exhibit abortive infection (56). However, these studies 
mainly focus on monocytes and monocytic cell types and have not studied VACV 
infection in B cells in any depth. In addition to PBMCs, VACV infection has been 
studied in B lymphocyte cell lines to not only examine the abortive infection but 
also the B cell function of antigen presentation. When the immature B 
lymphocyte line WEHI-231 was infected, VACV infection was abortive and 
induced apoptosis by downregulating Bcl-2 which protects from cell death (59). In 
contrast, a B lymphoblastoid cell line (B-LCL) displayed a productive VACV 
infection (58). When the effect of VACV infection on B cells was assessed, the 
same B lymphocyte cell line displayed no changes in expression levels of MHC 
class II, but MHC class II-mediated antigen presentation was dramatically 
disrupted by the alteration of the peptide association (63). In addition, this same 
ability to modulate the immune response to the infection in B cells was 
demonstrated in individuals naturally infected with VACV (64). Infected 
individuals revealed reduced levels of B cells when compared to uninfected 
individuals (64). Additionally, these B cells in infected individuals were less 
activated when CD80 and CD86 expression was examined (64).      
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B cell function and development 
 B cells, bursal or bone marrow-derived cells, were discovered and 
characterized the 1960s and 1970s around the time that T cells were discovered 
(65). The discovery of B cells began with discovering and identifying the 
immunoglobulin (Ig) protein, leading to the identification of antibody-producing 
cells (66). The remaining B cell subsets of the highly heterogeneous B cell 
population were discovered and identified after these pivotal discoveries. In 
1980, the first B cell-specific characterizing molecule, CD20, was described (67). 
Since the identification of immunoglobulins or antibodies being produced by 
antibody-producing B cells, several additional functions of B cells have been 
revealed. Antigen (Ag) processing and presentation to T cells is another crucial 
function of B cells. Ag presentation in B cells occurs when Ag is bound and 
internalized by the B cell receptor (BCR), processed, and presented on MHC (68-
70). B regulatory cells have described and regulate T cell-mediated inflammatory 
responses by producing anti-inflammatory cytokines (71, 72). Additionally, 
cytokine production to influence T cell differentiation and providing T cell 
costimulation are other functions of B cells. In addition to having a variety of 
functions, B cells display a range of cell surface phenotypes and locations.  
 B cell development begins in the bone marrow from common lymphocyte 
progenitors (Fig. 2). Common lymphocyte progenitors differentiate into pro-B 
cells and progress from pro- to pre-B cells by Ig heavy chain rearrangement (73, 
74). After positive selection for appropriate heavy chain rearrangement and light 
chain rearrangement, pre-B cells differentiate into immature B cells expressing 
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IgM that undergo negative selection to eliminate self-reactive cells (74, 75). 
Immature B cells then migrate from the bone marrow to the peripheral lymphoid 
tissue and gain expression of IgD to mature into transitional B cells (76). 
Transitional B cells undergo maturation into mature-naïve B cells migrating to 
lymphoid follicles before becoming activated by encountering Ag. These 
activated follicular B cells can then become germinal center (GC) B cells after 
receiving T cell help. GC B cells proliferate and class-switch the BCR constant 
region from IgM and IgD to IgM, IgG, IgA, or IgE (77). Moreover, the V region 
gene can undergo somatic hypermutation to change antibody (Ab) or BCR 
affinity (78, 79). These GC B cells can either become memory B cells or plasma 
cells. Long-lived plasma cells start as plasmablasts, while short-lived plasma 
cells can arise directly from activated B cells (80-82). 
  
  
1
7
 
 
Figure 2. B cell development. Overview of B cell development adapted from Cambier JC, Gauld SB, Merrell KT, Vilen 
BJ. 2007. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nature Reviews Immunology 
7:633. 
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B cells and the smallpox vaccination 
 Memory B cells and long-lived plasma cells are responsible for Ab 
production and release contributing to long-term immunity, following pathogen 
exposure or vaccination. A rapid recall Ab response is driven by memory B cells 
upon re-exposure to an Ag, and these cells aid in replenishing the pool of long-
lived plasma cells (83, 84). Meanwhile, long-lived plasma cells provide 
continuous serum Ab level maintenance (83, 85). The smallpox vaccination has 
been shown to generate a strong neutralizing Ab response that declines within 
the first 3-5 years, and the CDC recommends revaccination every 3 to 10 years, 
depending on exposure to specific poxviruses, to provide long-term protection 
(86, 87). However, studies have revealed long-term B cell memory to the 
smallpox vaccine (86, 88). Additionally, one study discovered vaccinia-specific 
IgG and neutralizing Abs at smallpox protective levels in individuals vaccinated 
more than 88 years earlier (89). These same memory cells are concentrated in 
the spleen (88). 
 While the generation of a long-term humoral response was remarkable for 
the smallpox vaccination, the eradication of smallpox and multiple adverse 
reactions lead to the termination of vaccine distribution to the public. Flu-like 
symptoms, generalized vaccinia, and myopericarditis were among the mild or 
moderate adverse reactions (90). The rare but potentially life threatening 
reactions include postvaccinal encephalitis, progressive vaccinia, and eczema 
vaccinatum (90). Eczema vaccinatum is a serious local or disseminated rash 
caused by widespread infection of the skin in individuals with eczema or atopic 
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dermatitis post-vaccination. Due to this potential reaction, individuals with 
eczema or atopic dermatitis are suggested to forego VACV vaccination. 
Additionally, 18 to 30 million individuals have eczema in the United States (91). 
Among other alterations in the immune system, these individuals have 
significantly higher frequencies of transitional B and chronically activated memory 
B cells (92).  
 
Summary of findings 
 Here, I investigated VACV binding to and infection of primary human B 
cells at various stages of cell maturation and differentiation in peripheral blood. I 
found that plasmablasts were resistant to VACV binding, while B cells in other 
maturation stages exhibited no defects in VACV binding. Plasma and mature 
naïve B cells were resistant to VACV infection, while memory B cells were 
susceptible to VACV infection. VACV infection in ex vivo B cells was aborted at 
the late stage of viral gene expression. Additionally, VACV binding and infection 
was increased in larger and proliferative B cells suggesting a bias of VACV 
infection towards either specific stages of differentiation and proliferative ability or 
cell surface area. In contrast to ex vivo B cells, stimulated B cells were 
permissive to productive VACV infection. Additionally, this work highlights the 
potential of B cells as natural cellular models to identify VACV receptors or 
dissect the molecular mechanisms underlying key steps of the VACV life cycle 
such as binding, penetration, entry, and replication in primary human cells. The 
understanding of VACV biology in human primary cells is essential for the 
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development of a safe and effective live-virus vector for oncolytic virus therapy 
and vaccines against smallpox, other infectious diseases, and cancer. 
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Chapter II - Materials and Methods 
  
Antibodies and flow cytometry (FCM) 
Table 1 shows anti-human monoclonal antibodies conjugated with 
fluorochromes that were purchased from BD Biosciences (San Jose, CA) or 
Biolegend (San Diego, CA). These panels of fluorochrome-conjugated antibodies 
were used for cell surface staining of isolated B cells to analyze the B cell 
phenotypes noted in Table 2. Some of these fluorochrome-conjugated antibodies 
such as CD69FITC, CD83PE, CD80PE-Cy7, and CD86BV510 were also used for cell 
surface staining to evaluate B cell activation. All four panels include CD20, CD38, 
CD27, and IgD to allow for rudimentary phenotyping of B cell subsets. Panel 1 
explores chemokine receptor expression, and panel 2 examines activation as 
well as B cell maturation. Panel 3 includes markers to further define memory B 
cells and their activation state. Plasma cells are the focus of panel 4. Additional 
anti-human monoclonal antibodies conjugated with fluorochromes were 
purchased from BD Biosciences (San Jose, CA): anti-CD69FITC, anti-CD83PE, and 
matched-isotype control antibodies conjugated with FITC and PE. Anti-human 
CD80 and CD86 antibodies were purchased from Biolegend (San Diego, CA). 
Unstimulated and stimulated B cells were subjected to surface staining with 
different combinations of antibodies focused on B cell phenotypic markers and/or 
activation markers. Proliferation was assessed by Ki-67 (BD Biosciences, San 
Jose, CA) intracellular staining with cold 70% ethanol used to fix and 
permeabilize the cells. Appropriate isotype controls were used at the same 
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protein concentration as the test antibodies for control staining, which was 
performed during every flow cytometric analysis. After cell surface staining, B 
cells were subjected to fixation by 2% paraformaldehyde (PFA) and followed by 
flow cytometric analysis using the BD FACSCalibur (BD Biosciences, San Diego, 
CA) or BD LSRFortessa (BD Bioscience, San Diego, CA). The data were 
analyzed using FlowJo software (Tree Star, San Carlos, CA).  
 B cell viability and functionality were detected using calcein AM 
(Invitrogen, Carlsbad, CA). Calcein AM is a non-fluorescent, hydrophobic 
compound readily absorbed by cells. Upon hydrolysis of the compound by 
endogenous intracellular esterases, calcein AM becomes calcein, a hydrophilic 
fluorescent compound, and remains in the cytoplasm of cells with intact 
membranes. Briefly, B cells were labeled at 37°C for 30 min with 1 μM calcein 
AM. The cells were washed three times with PBS to remove free calcein AM and 
then resuspended with 2% FBS in PBS to run FCM. The control sample was 
prepared by mixing live with dead cells, generated by treating an aliquot of cells 
with 70% methanol for 30 minutes before washing thoroughly with PBS.  
 Propidium iodide (PI) was used for cell cycle analysis. For this assay, 
isolated B cells were fixed in ice cold 70% ethanol in a dropwise fashion to 
ensure complete fixation for 30 min at 4°C. Cells were then washed and treated 
with RNase H (Invitrogen, Carlsbad, CA) to prevent PI binding to RNA. After 
RNase treatment, cells were stained with 200ul of 50ug/ml PI (BD Pharmingen, 
San Jose, CA). B cells were resuspended with 2% FBS in PBS to run FCM using 
the BD Accuri C6 Plus (BD, Biosciences, San Diego, CA). 
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Table 1. B cell phenotyping antibody panels. 
Panel 1 Panel 2 Panel 3 Panel 4 
CCR7
PE
 CD23
PE
 CD86
PE
 BCMA
PE
 
PI PI PI PI 
HLA-DR
PerCP-Cy5.5
 CD69
PerCP-Cy5.5
 IgM
PerCP-Cy5.5
 CD10
PerCP-Cy5.5
 
CXCR4
PE-Cy7
 CD40
PE-Cy7
 CD80
PE-Cy7
 CD138
PE-Cy7
 
CXCR5
AF647
 CD21
AF647
 CD226
AF647
 TACI
AF647
 
IgD
AF700
 IgD
AF700
 IgD
AF700
 IgD
AF700
 
CD20
APC-Cy7
 CD20
APC-Cy7
 CD20
APC-Cy7
 CD20
APC-Cy7
 
CD38
BV421
 CD38
BV421
 CD38
BV421
 CD38
BV421
 
CD27
BV510
 CD27
BV510
 CD27
BV510
 CD27
BV510
 
CCR6
BV605
 CD25
BV605
 CD45RA
BV605
 CD24
BV605
 
 
Four panels of antibodies used for examining B cell phenotypes in uninfected 
and VACV-infected B cells. 
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Table 2. Phenotypes of primary peripheral B cell subsets.   
B cell subset Phenotypic markers Reference 
transitional CD19
+
CD38
+
CD24
+
 Morbach et al 
mature naïve  CD19
+
IgD
+
CD27
-
CD21
+
 
Morbach et al; 
Kaminski et al 
memory CD19
+
CD27
+
 Morbach et al 
non-switched memory CD19
+
CD27
+
IgD
+
IgM
+
 Morbach et al 
IgM only memory CD19
+
CD27
+
IgD
-
IgM
+
 
Morbach et al; 
Kaminski et al 
class-switched memory CD19
+
CD27
+
IgD
-
IgM
-
 
Morbach et al; 
Kaminski et al 
plasmablasts CD19
+
CD20
lo
CD138
-
CD38
+
CD27
+
 Morbach et al 
plasma cells CD19
+
CD20
+
CD138
+
 
Morbach et al;  
Kaminski et al 
 
Cell surface markers used to define the specific B cell subsets. 
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VACV production, titration, and infection protocols 
 The primary VACV strain used in this study was Western Reserve (WR). 
The EGFP reporter virus, denoted as VV-EGFP hereinafter, is a WR strain 
containing a chimeric gene including the influenza virus nucleoprotein, the 
ovalbumin SIINFEKL peptide, and enhanced green fluorescence protein (EGFP) 
regulated by the P7.5 early/late promoter that localizes to the nucleus (93). Both 
VACV WR and VV-EGFP were obtained from Dr. Jonathan Yewdell (NIH, 
Bethesda, MD). vA5L-YFP, obtained from Dr. Bernard Moss (NIH, Bethesda, 
MD), is a recombinant WR VACV constructed with the viral core protein A5L 
fused to yellow fluorescence protein (YFP) suitable for visualizing individual 
virions (94). All viral stocks were generated and titrated in the monkey kidney cell 
line CV-1 (ATCC, Manassas, VA) in RPMI-1640 medium supplemented with 10% 
FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 U/mL streptomycin 
(complete RPMI-1640). After approximately 3 to 4 days of infection, cells were 
lysed in a dounce homogenizer. Culture supernatants and cell lysates were then 
subjected to ultracentrifugation at 25,000 g for 80 min through a 36% sucrose 
cushion, and pellets were resuspended and subjected to virus plaque assays to 
determine the viral titers. Briefly, CV-1 cells were grown in 12-well plates to over 
90% confluency and overlaid with various dilutions of virus stock. After 2 h of 
incubation, cells were washed and overlaid with complete RPMI-1640 containing 
1% carboxylmethylcellulose to prevent de novo plaque formation. After 3 days of 
culture, cells were washed and stained with a 0.01% crystal violet with 15% 
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ethanol solution and then washed to visualize plaques for counting to calculate 
virus plaque-forming units (PFU).  
This study used the single-enveloped IMV particles of all VACV strains 
(vA5L-YFP, VV-EGFP, and WR) due to the abundance (>98%) and stability of 
the membrane even after freezer storage (15, 95). The double-enveloped forms 
of VACV, EEV and CEV, are difficult to maintain for long periods on time due to 
the deceased stability of the secondary membrane, not found on the IMV form. 
 For infections involving virus plaque assay analysis, stimulated or 
unstimulated primary B cells in 24-well plates (approximately 1 million cells per 
well) were incubated with VACV WR at a multiplicity of infection (MOI) of 2 for 1 
h, washed three times with PBS, and cultured for 2 days in complete RPMI-1640. 
Cells and culture supernatants were harvested at various time points, and cells 
were lysed by three rounds of freezing and thawing, followed by cup horn 
sonication. Cell lysates and supernatants were either analyzed separately or 
mixed together for determination of virus titers.  
For VACV binding assays, stimulated or unstimulated primary B cells were 
chilled on ice to 4°C and incubated with vA5L-YFP at a MOI of 0.5 on ice for 30 
minutes with gentle mixing. Cells were washed three times with ice-cold PBS, 
fixed with 2% PFA, and YFP-positive cells were quantitated using FCM. VV-
EGFP was used to monitor viral early gene expression in B cells as an indication 
of VACV infection. After either 12 or 24 h, cells were fixed with 2% PFA and 
EGFP-positive cells were quantitated using FCM.  
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For infections involving RT-PCR analysis, stimulated or unstimulated 
primary B cells in 48-well plates (approximately 1 million cells per well) were 
incubated with VACV WR at a MOI of 2 for 1 h, washed three times with PBS, 
and cultured for various time points in complete RPMI-1640. Cells were 
harvested at various time points and subjected to RNA isolation. Multiplex 
analysis VACV infection were performed by stimulated or unstimulated primary B 
cells in 24-well plates (approximately 0.5 to 1 million cells per well) being 
incubated with VACV WR at a MOI of 2 under the aforementioned VACV binding 
conditions, washed three times with PBS, and cultured for various times in 
complete RPMI-1640. Culture supernatants were harvested at various time 
points and underwent multiplex analysis to assess cytokine production. 
 
Ethics statement 
 Peripheral blood or leukapheresis samples from healthy blood donors 
were obtained under an IRB protocol approved by the Indiana University School 
of Medicine Institutional Review Board for Human Research (Indianapolis, IN). 
Written informed consent was obtained from each participant before specimen 
collection. 
 
Preparation of human PBMCs and B cell isolation and activation 
 Whole blood samples from healthy donors or leukapheresis products from 
the Indiana Blood Bank were obtained from healthy blood donors with written 
consent obtained from each participant. Investigational protocols were approved 
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by Institutional Review Boards for Human Research at the Indiana University 
School of Medicine (Indianapolis, IN). Peripheral blood mononuclear cells 
(PBMCs) were isolated from the whole blood or leukapheresis products using the 
gradient centrifugation on Ficoll-Hypaque (Amersham Pharmacia Biotech AB, 
Uppsala, Sweden). Isolated PBMCs were subjected to immunomagnetic positive 
selection of B cells using Human CD19 Microbeads (Miltenyi Biotec, Auburn, 
CA). Resulting cell preparations contained more than 97% purity of the B cells 
when assessed by CD19 staining of an alternate epitope and FCM.  
Purified B cells were cultured in the presence of 20 ug/ml AffiniPure 
F(ab’)2 Goat Anti-Human IgG + IgM (H+L) (Jackson Immunoresearch 
Laboratories, West Grove, PA) and 50 nM TLR9 agonist CpG ODN 2006 
(InvivoGen, San Diego, CA) in complete RPMI 1640 medium for 24 h at 37°C. 
Supernatants were subjected to enzyme-linked immunosorbent assays (ELISAs) 
of IL-6 and IL-10 to evaluate B cell activation. Human IL-6 DuoSet (R&D 
Systems, Minneapolis, MN) and IL-10 (Life Technologies, Carlsbad, CA) ELISA 
kits were used according to the manufacturer’s instruction.  
 
Confocal microscopy 
 For binding assays, B cells were incubated with vA5L-YFP VACV at a MOI 
of 10 under the aforementioned binding conditions. Infections for entry assays 
were performed by incubating B cells with VV-EGFP at a MOI of 10. We have 
previously shown that VACV binds to proteins within or near lipid rafts (61), and 
hence lipid rafts were used to mark the cell surface to indicate the location of the 
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virus. For lipid raft staining, cells were incubated with cholera toxin subunit B 
(CTB) conjugated with Alexa Fluor 647 (Life Technologies, Carlsbad, CA) at 4°C 
for 20 min to stain ganglioside M1 (GM1).To detect extracellular virions, cells 
were incubated with rabbit polyclonal antiserum NR-631 against the VACV WR-
encoded L1R protein (obtained through the NIH Biodefense and Emerging 
Infections Research Resources Repository, NIAID, NIH) followed by secondary 
antibody staining of donkey anti-rabbit IgG (H+L) conjugated to Alexa Fluor 546 
(Life Technologies, Carlsbad, CA). Cells were mounted onto glass slides using 
ProLong Gold Antifade reagent (Life Technologies, Carlsbad, CA) containing 
4’,6-diamidino-2-phenylindole (DAPI) dye for DNA staining. Slides were viewed 
using an Olympus FV1000-MPE confocal/multiphoton microscope fitted with a 
60X water objective. Images were processed using ImageJ version 1.47 software 
(NIH, Bethesda, MD). 
 
RT-PCR analysis of VACV gene expression analysis 
 Stimulated or unstimulated primary B cells were incubated with VACV WR 
at a MOI of 2 for 1 h, washed with PBS, and cultured for various time points in 
complete RPMI 1640 medium. Cells were harvested, washed two times in PBS, 
and subjected to RNA extraction using the RNeasy Mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. RNA was subjected to 
cDNA synthesis using the Superscript III First Strand synthesis kit (Life 
Technologies, Carlsbad, CA) according to the manufacturer’s instructions. RT-
PCR was performed using the Taq PCR Master Mix kit (Qiagen, Hilden, 
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Germany) with primers against VACV early, intermediate, and late genes, 
including: A23R forward, 5’-CGTTAGTAACGCCATATGGATAATCTATTTACC-3’ 
and A23R reverse 5’-ACCCTAGTCGTTGGATCCATTTCTGAATC-3’; C11R 
forward, 5’-CAGATCATTCGCCGATAGTGGTAAC-3’ and C11R reverse 5’-
GGTAGTTTAGTTCGTCGAGTGAACCT-3’; A2L forward, 5’-
TCGTGTCCATAATCCTCTACCAT-3’ and A2L reverse 5’-
TCCACGGATGATGTAGATGCAAA-3’; G8R forward, 5’-
GGCGGATCTGTAAACATTTGGG-3’ and G8R reverse 5’-
TCCTCGTAGTTTGTTGAGAGACG-3’; A17L forward, 5’-
GGGCCATGGCTTATTTAAGATATTACAATATGCTT-3’ and A17L reverse 5’-
GGGGGATCCTTAATAATCGTCAGTATTTAAACT-3’; B7R forward, 5’-
TATCGGATCCAATAATGAGTACACTCCG-3’ and B7R reverse 5’-
GAGCGAATTCTTAAAAATCATATTTTGA-3’ (Life Technologies, Carlsbad, CA). 
Expression data was analyzed for presence of gene expression at particular time 
points as an indication of VACV infection progression.  
 
Multiplex analysis 
 Stimulated or unstimulated primary B cells from 6 individual healthy blood 
donors were incubated with VACV WR at a MOI of 2 under the aforementioned 
VACV binding conditions, washed with PBS, and cultured for various times in 
complete RPMI 1640 medium. Culture supernatants were harvested at various 
time points and subjected to multiplex analysis to assess cytokine production. 
The concentrations of 45 human cytokines, chemokines, and growth factors 
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(BDNF, Eotaxin/CCL11, EGF, FGF-2, GM-CSF, GRO alpha/CXCL1, HGF, NGF 
beta, LIF, IFN alpha, IFN gamma, IL-1 beta, IL-1 alpha, IL-1RA, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12 p70, IL-13, IL-15, IL-17A, IL-18, IL-21, 
IL-22, IL-23, IL-27, IL-31, IP-10/CXCL10, MCP-1/CCL2, MIP-1 alpha/CCL3, MIP-
1 beta/CCL4, RANTES/CCL5, SDF-1 alpha/CXCL12, TNF alpha, TNF beta/LTA, 
PDGF-BB, PLGF, SCF, VEGF-A, and VEGF-D) in the supernatants of B cells 
cultured for various times with and without VACV were simultaneously measured 
using the ProcartaPlex Human Cytokine/Chemokine/Growth Factor Panel 1 
45plex kit (Invitrogen, Carlsbad, CA) as per the manufacturer’s instructions. The 
standards were performed on each plate in duplicate, and all samples from a 
particular donor were assayed concurrently on the same plate to avoid interassay 
variability. Data were acquired using a Luminex-100 system and analyzed using 
Bio-Plex Manager Software (Applied-Cytometry). 
 
Statistical analysis 
 Data from two groups were analyzed using the Student t test or paired t 
test, and data from three or more groups were analyzed using either ANOVA with 
Tukey’s post hoc test or paired ANOVA with Tukey’s post hoc test. Two-way 
ANOVA with Bonferroni post-test was used to analyze subset or marker data 
between the two groups within the isolated cells. P values of < 0.05 were 
considered statistically significant. 
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Chapter III – Results 
 
B cell subset frequency in ex vivo B cells 
 As B cells were the main focus of this study, the cell subsets in ex vivo 
isolated B cells were examined to confirm that our blood donors displayed similar 
frequencies as other studies. The surface markers for the five main subsets and 
three memory subtypes came from a combination of Morbach et al and Kaminski 
et al, with Morbach et al providing the main surface markers and Kaminski et al 
providing refinement and further delineation of specific populations (Table 2) (96, 
97). The CD27-IgD+ naïve B cell subset was further narrowed down to mature 
naïve B cells, which express CD21 (97), due to transitional B cells also displaying 
these markers (97). Additionally, CD24-CD38hi plasmablasts display markers 
found on both plasmablasts and plasma cells, therefore CD138, typically found 
on plasma cells, was used to differentiate between the two cell types. The 
frequencies of the different B cell subsets in this study were comparable to 
Morbach et al (Fig. 3a, 3b) (96). Additionally, over 80% and 60% of B cells 
expressed CXCR5 or CXCR4, respectively (Fig. 3c). 
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Figure 3. B cell subset frequency in ex vivo B cells. A) Representative FCM 
plots for the evaluation of specific B cell populations using the four B cell 
phenotyping panels from Table 1. B) Distribution of B cell subsets in ex vivo B 
cells. C) Percentage of cells expressing specific surface molecules. Graphs 
represent mean ± SEM; n= 5. NS, non-switched memory; CS, class-switched 
memory; IgM, IgM only memory. 
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VACV robustly bound to but weakly infected ex vivo B cells 
 Previous studies using primary human PBMCs have shown that APCs, 
including B cells, displayed strong VACV binding (56, 61), while only minimal 
viral entry and infection was seen in B cells (56, 60, 61, 98). To better understand 
this difference between binding and infection, we first examined if this disparity 
was recapitulated in isolated B cells by assessing VACV binding and infection in 
isolated B cells. Ex vivo B cells were incubated with a MOI 0.5 of vA5L-YFP 
particles at binding conditions, 4°C for 30 min, to study VACV binding to isolated 
B cells, purity >97% CD19+ (data not shown). VACV bound robustly to isolated B 
cells, 61.8 ± 3.3% of total B cells (Fig. 4a, 4b). These values were the results of 
the mean ± standard error of the mean (SEM) from seven healthy blood donors. 
These data demonstrated that isolated B cells displayed similar levels of virus 
binding as seen in PBMCs (Fig. 4b) (61). VACV infection was minimal , 12.6 ± 
1.5% of total B cells, compared to binding which corresponds with previous 
studies in PBMCs showing low infection rates of B cells (Fig. 4a, 4b) (61). Upon 
further analysis, we found VACV binding displayed a bias towards CD19+CD20hi 
rather than CD19+CD20lo B cells, while VACV infection exhibited no statistically 
significant increase in infection of CD19+CD20hi B cells (Fig. 4c). However, VACV 
infection displayed a bias towards CD19+CD20hi rather than CD19+CD20lo B cells 
when assessed on an individual donor basis. Binding assessed by viral encoded 
YFP gene expression suggests that CD20hi B cells are more sensitive to VACV 
binding, whereas CD20lo B cells are more resistant to VACV binding. Thus, 
VACV binding and infection in isolated B cells closely reflected the results seen 
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in PBMCs (56, 61) and showed a bias towards CD20hi transitional, mature naïve, 
and memory B cells compared to CD20lo or CD20- B cells, typically plasmablasts 
and plasma cells. 
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Figure 4. Limited VACV infection in primary B cells despite robust VACV 
binding. Analysis of VACV binding and infection (24h) at MOI 1 in isolated 
primary human B cells. A) Representative FCM plots for VACV binding and 
infection. B) Pooled data of VACV binding and infection of primary B cells from 
seven healthy donors. C) Analysis of VACV binding (vA5L-YFP) and infection 
(VV-EGFP) in CD19+CD20hi and CD19+CD20lo B cells. Graphs represent mean ± 
SEM. ***, p < 0.001. HD, healthy donor; mock, uninfected B cells.  
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Plasmablasts displayed resistance to VACV binding 
 B cells are highly heterogeneous with many subtypes and fully defining 
the various subtypes in humans is still in progress. CD19 and CD20 are only two 
of many markers that are used to differentiate between the different B cell 
subsets. CD19 is considered a pan-B cell marker and widely expressed during all 
B cell differentiation and maturation phases found in peripheral blood except 
some terminally differentiated B cells. CD20 is commonly expressed on most 
mature B cell subsets except for plasmablasts and most plasma cells. To better 
understand VACV infection in primary B cells, VACV binding to specific B cell 
subtypes was evaluated by FCM (Fig. 5). VACV displayed robust binding to the 
majority of the main peripheral B cell subsets when comparing bound and 
unbound cells within each specific B cell subset (Fig. 5a, 5b). Plasma, 
transitional, mature naïve, and memory B cells exhibited the most robust VACV 
binding. In contrast, plasmablasts exhibited minimal VACV binding (Fig. 5a, 5b). 
Amongst the memory B cells subtypes, class-switched memory displayed 
decreased VACV binding compared to non-switched and IgM memory cells. 
Although the receptors for poxviruses have yet to be discovered, one study 
suggested that poxviruses use chemokine receptors to bind to and enter into 
cells (99). Since poxviruses have been shown to have an association with 
chemokine receptors, we examined VACV binding to B cells expressing CXCR4 
or CXCR5. VACV displayed no preferential binding to CXCR4 or CXCR5 
expressing cells (Fig. 5c). Additionally, VACV binding to B cells expressing 
activation markers, such as CD80 and CD86, revealed large percentages of 
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VACV-bound cells (Fig. 5c). B cells can express many of these chemokine 
receptors and activation markers concurrently; however, this work focused on 
individual receptors or markers. 
In addition to evaluating VACV binding to specific B cell populations, 
expression of markers for specific B cell subsets, activation, or potential VACV 
receptors were evaluated in YFP-positive, VACV-bound cells. The greater part of 
the VACV bound B cells were mature naïve and memory B cells, whereas 
plasma cells and plasmablasts made up only a small portion of the VACV-bound 
cells (Fig. 6a). As expected, the distribution of the B cell subsets in the VACV-
bound cells (Fig. 6) was similar to the distribution seen in the mock infected B 
cells (Fig. 3). Evaluation of specific activation markers and possible poxvirus 
receptors in VACV-bound cells revealed greater than 90% of VACV-bound cells 
were positive for CXCR5, and more than 55% of VACV-bound cells were 
CXCR4+ (Fig. 6b). In contrast, less than 15% of the VACV-bound cells were 
CD80- or CD86+ (Fig. 6b). These results resemble the distribution noted in 
mock-infected B cells, suggesting that chemokine receptors, especially CXCR4, 
may not play a major role in VACV binding. 
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Figure 5. Plasmablasts displayed resistance to VACV binding. Evaluation of 
VACV binding (vA5L-YFP at MOI 0.5) in specific B cells populations and B cells 
expressing certain markers using the four B cell phenotyping antibody panels 
from Table 1. A) Representative FCM of VACV binding in five major B cell 
subsets found in peripheral blood and three subtypes of memory B cells. B) 
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Pooled data of VACV binding in B cell subsets. The three colors represent 
different groups when comparing binding and infection result patterns. Blue, high 
binding and low infection; red, low binding and low infection; green, high binding 
and high infection. C) Analysis of VACV binding to B cells expressing common 
activation markers and chemokine receptors. Graphs represent mean ± SEM. **, 
p < 0.01; ***, p < 0.001; ##, p < 0.01. *, denotes ANOVA results for the five B cell 
subsets (transitional, mature naïve, memory, plasmablasts, and plasma cells); #, 
denotes ANOVA results for the three memory subtypes (non-switched, IgM, and 
class-switched). ns, not significant. 
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Figure 6. Higher frequency of mature naïve and memory B cells in VACV-
bound cells. Evaluation of B cell subsets and surface molecule in the VACV-
bound population. A) Percentage of cells displaying specific B cell phenotypes in 
the VACV-bound cells. B) Percentage of cells displaying specific markers in the 
VACV-bound cells. Graphs represent mean ± SEM; n=5. *, p < 0.05; ***, p < 
0.001; #, p < 0.05. *, ANOVA results for the five B cell subsets (transitional, 
mature naïve, memory, plasmablasts, and plasma cells); #, ANOVA results for 
the three memory subtypes (non-switched, IgM, and class-switched).  
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 B cell subset frequency in incubated B cells 
Along with measuring the frequencies of B cells subsets ex vivo, we also 
determined subset frequencies in the mock infected cells that had been 
incubated for 12 h in complete RPMI-1640, the same length of time as the VACV 
infection. These experiments were conducted with the three donors with a 
sufficient number of cells for both the ex vivo and 12 h infection experiments. The 
majority of the subsets, including plasmablasts, mature naïve, transitional, and 
IgM only memory B cells, remained relatively similar post-incubation (Fig. 7a) 
compared to ex vivo (Fig. 3b) B cells (Fig. 8a). Although no significant changes in 
frequency of certain B cell subsets was noted, plasma cells displayed a slightly 
increased frequency, while memory, non-switched and class-switched, B cells 
showed a slight decrease (Fig. 8a). Additionally, the percentage of cells 
expressing CXCR4 was increased and CCR6 expressing cells decreased 12 h 
post-incubation (Fig. 7b, 8b). Of note, the percentage of CD80 and CD86 
expressing cells was not increased despite VACV infection, but the frequency of 
CXCR4 expressing cells increased, suggesting that incubation of B cells could 
lead to activation (Fig. 8b). 
 
Plasma and mature naïve B cells displayed a resistance to VACV infection 
 Since VACV displayed a disparity between binding and infection of B cells 
as well as a difference in binding to specific subsets, we sought to assess VACV 
infection in specific B cell subsets by FCM. Three patterns emerged when 
binding and infection were compared to each other. Memory B cells and their 
 43 
subtypes permitted a large portion of the bound virus to enter into the cells, and 
there was no difference between the different memory subtypes (Fig. 9a, 9b). 
These memory B cells and subtypes displayed the first pattern, which was 
relatively high VACV binding rates and high VACV infection rates. However, 
memory B cells comprised less than 32% of the total B cells in this study. Taking 
this into account, the robust infection of memory B cells was moderated when 
considering VACV infection in total B cells because of the reduced percentage of 
this population compared to the rest of the resistant subtypes. VACV binding to 
plasma, transitional, and mature naïve B cells was also robust, but few of these 
VACV-bound cells displayed viral entry (Fig. 9a, 9b), which suggests these cells 
were either resistant to VACV entry or suppressed viral gene expression. The 
final pattern observed was noted in plasmablasts which displayed low VACV 
binding as well as low viral infection. Additionally, there was no difference in 
VACV infection between cells expressing chemokine receptors (Fig. 9c). Of the 
CD80+ or CD86+ B cells, the percentage of VACV-infected cells was below 10% 
and just above 30% of the population, respectively (Fig. 9c).  
Examination of B cell populations in VACV-infected cells revealed memory 
B cells, specifically class-switched memory, were the dominate B cell subtype in 
the VACV-infected cells (Fig. 10a). The remaining B cell subtypes were minimal 
in the VACV-infected cells (Fig. 10a). These data correspond to the pattern of 
percentages of these memory subtypes in incubated cells (Fig. 7a, 8a). Of note, 
the percentage of VACV-infected B cells with a mature naïve phenotype (Fig. 
10a) did not correspond to the pattern of mature naïve B cell percentage among 
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other B cells (Fig. 7a, 8a). These data may reflect a resistance to VACV infection 
or an alteration of cell surface markers by VACV infection.  
Although >90% of the VACV-infected cells expressed CXCR4 and CXCR5 
(Fig. 10b), less than 15% of B cells expressing CXCR4 or CXCR5 were infected 
with VACV (Fig. 9b), suggesting that the expression of chemokine receptors 
CXCR4 and CXCR5 is not the only factor involved in VACV entry. However, 
despite the decrease in the percentage of CCR6 expressing cells (Fig. 8b), a 
higher percentage, compared to the other chemokine receptors, of CCR6 
positive cells were VACV infected (Fig. 9c).  
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Figure 7. B cell subset frequency in incubated B cells. A) Distribution of B 
cell subsets in B cells incubated for 12 h. B) Percentage of cells expressing 
specific surface molecules. Graphs represent mean ± SEM; n= 3.  
 
 
 
 
 
 46 
 
Figure 8. Comparison of B cell subset frequency between ex vivo and 
incubated cells. A) Distribution of B cell subsets in B cells either ex vivo or 
incubated for 12 h. B) Percentage of cells expressing specific surface molecules 
between ex vivo or incubated for 12 h B cells.  Graphs represent mean ± SEM; 
n= 5 for ex vivo and n=3 for incubated. *, p < 0.05; ***, p < 0.001. ns, not 
significant. 
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Figure 9. Plasma and mature naïve B cells displayed resistance to VACV 
infection. Evaluation of VACV infection (VV-EGFP at MOI 0.5; 12 h.p.i.) in 
specific B cells populations and B cells expressing certain markers using the four 
B cell phenotyping antibody panels from Table 1. A) Representative FCM plots 
for VACV infection (12 h.p.i.) in specific B cell subsets. B) VACV infection (12 
h.p.i.) in five major B cell subsets found in peripheral blood and three subtypes of 
 48 
memory B cells. The three colors represent different groups when comparing 
binding and infection result patterns. Blue, high binding and low infection; red, 
low binding and low infection; green, high binding and high infection. C) VACV 
infection (12 h.p.i.) in cells expressing common activation markers and 
chemokine receptors. Graphs represent mean ± SEM. **, p < 0.01; ***, p < 0.001. 
*, ANOVA results for the five B cell subsets (transitional, mature naïve, memory, 
plasmablasts, and plasma cells).  
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Figure 10. Higher frequency of memory B cells in VACV-infected cells. 
Evaluation of B cell subsets and surface molecule in the VACV-infected 
population. A) Percentage of cells displaying specific B cell phenotypes in the 
VACV-infected cells. B) Percentage of cells displaying specific markers in the 
VACV- infected cells. Graphs represent mean ± SEM; n=3. ***, p < 0.001; ##, p < 
0.01. *, ANOVA results for the five B cell subsets (transitional, mature naïve, 
memory, plasmablasts, and plasma cells); #, ANOVA results for the three 
memory subtypes (non-switched, IgM, and class-switched).  
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Abortive VACV infection in isolated CD19+ B cells at late stage of VACV 
gene expression 
 In addition to examining the B cell subsets preferentially bound or infected 
by VACV, we sought to better understand VACV infection in primary human B 
cells. Therefore, we examined the progression of VACV infection in isolated B 
cells. To our knowledge, the progression of VACV infection has only been 
examined in B cell lines, and VACV infection in cell lines varies greatly from 
infection in primary human cells (56, 61, 98). However, one study determined the 
permissiveness of VACV infection in PBMCs and noted that VACV infection in B 
cells was abortive (56). To confirm VACV infection in B cells is abortive, plaque 
assays were completed on B cells infected with VACV at a MOI of 2 to measure 
the production of new infectious virions. In ex vivo VACV-infected B cells, viral 
titers did not significantly change over a 48-hour period suggesting virions were 
not produced during the infection (Fig. 11). Although the abortive VACV infection 
in B cells was confirmed, the stage at which the infection was aborted is still 
unknown.  
To determine at which step in the virus infectious cycle VACV infection 
was halted, the VACV life cycle was systematically examined. The VACV binding 
observed via FCM by evaluating the percentage of YFP-positive cells (Fig. 4) 
was confirmed by confocal microscopy. Confocal microscopy of vA5L-YFP 
incubated and CTB-stained, stains GM1 in lipid rafts, B cells showed no 
significant defects in viral binding as seen by the colocalization of the green and 
red signals in the form of yellow signals (Fig. 12). Additionally, confocal 
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microscopy of vA5L-YFP incubated and L1-stained, envelope protein of VACV, B 
cells exhibited no significant defects in viral binding as seen by the colocalization 
of the green (uncoated virion) and red (virus envelope) signals in the form of 
yellow signals and entry as green signals signifying uncoated virions (Fig. 13a). 
Moreover, VACV entry was evaluated via confocal microscopy by incubating B 
cells with VACV-EGFP virions for several hours and staining with CTB to detect 
lipid rafts. Detection of VACV entry and early gene expression was indicted by 
detecting green signals from the reporter virus with EGFP under an early/late 
promotor. Confocal microscopy assessing viral entry showed no defects in viral 
entry and early gene expression as green signals in the absence of red signals 
were present (Fig. 13b). VACV entry and early VACV gene expression was 
confirmed by using VACV-EGFP but assessing via FCM to also allow for 
quantification (Fig. 4).  
As viral binding and entry were not the limiting steps and VACV replication 
strictly follows a sequential life cycle (Fig. 1), viral gene expression is the 
subsequent step after entry and thus was measured by RT-PCR. Two genes of 
early, intermediate, and late viral gene expression temporal stages were 
assessed. C11R and A23R were the early genes assessed. C11R encodes a 
growth factor homologous to epidermal growth factor (100), while A23R encodes 
one of two subunits of vaccinia virus intermediate transcription factor (VITF) (37). 
Intermediate genes A2L and G8R both encode vaccinia virus late transcription 
factors (VLTF) VLTF-3 and VLTF-1, respectively (53, 54). Additionally, the late 
genes A17L, encoding an IMV membrane protein (101), and B7R, encoding a 
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polypeptide involved in dermal virulence (102), were assessed. Early and 
intermediate gene expression occurred in ex vivo B cells (Fig. 14). Interestingly, 
VACV late gene expression was minimal despite the expression of VLTF-1 and -
3 mRNAs, encoded by G8R and A2L respectively (Fig. 14). Thus, abortive VACV 
infection in primary B cells was most likely due to the failure to produce the late 
viral gene products which are important for viral assembly, structure and 
virulence.  
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Figure 11. VACV infection in isolated B cells was abortive. Examination of 
VACV replication in unstimulated B cells. A) Representative plaque assay using 
unstimulated B cells infected with VACV-WR at a MOI of 2 for various time points 
after incubation under binding conditions. B) Pooled data from virus plaque 
assays. Each dot in a group represents data from a single individual; n=3. ns, not 
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significant; PFU, plaque forming unit; h.p.i., hours post-infection. Lines represent 
mean ± SEM.
 55 
 
Figure 12. VACV binding to lipid rafts. Evaluation of VACV binding to 
unstimulated B cells. CTB stained lipid rafts, and vA5L-YFP (MOI 10) was the 
VACV reporter virus. Blue signal was DAPI for staining the nuclei. n=2. Scale 
bars represent 5 μM. 
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Figure 13. VACV entry into ex vivo B cells. Evaluation of VACV entry into 
unstimulated B cells. A) Confocal microscopy of VACV binding and entry. L1 was 
the IMV envelope protein, and vA5L-YFP (MOI 10) was the VACV reporter virus. 
n=3. B) Confocal microscopy of VACV entry and early gene expression in B cells. 
CTB stained lipid rafts, VV-EGRP (MOI 10) was the VACV reporter virus, and 
DAPI stained nuclei. n=2. Scale bars represent 5 μM. 
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Figure 14. VACV infection in isolated B cells was aborted at late gene 
expression stage. Examination of VACV-WR gene expression by RT-PCR. 
VACV early (C11R and A23R), intermediate (A2L and G8R), and late (A17L and 
B7R) gene expression in unstimulated B cells was assessed by RT-PCR. 0 h 
was cells incubated with VACV under binding conditions, washed in cold PBS, 
and subjected to immediate RNA isolation. n=2. 
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Cytokine production was unaffected by VACV infection in ex vivo B cells 
To more completely understand VACV infection in primary B cells, we 
assessed B cell function during VACV infection by examining cytokines, 
chemokines, and growth factors production via multiplex analysis. Due to the low 
sample size and high variation between donors, there was no significant 
differences between mock- and VACV-infected B cells during the various time 
points (Table 3). Comparing uninfected and infected cells from 6 donors revealed 
the trend of decreased and increased cytokine production in 8 h.p.i. and 24 h.p.i. 
infected cells, respectively (Table 3). Additionally, using 3 h.p.i. as the baseline 
and examining the trends, infected cells exhibited predominately a decrease or 
no change in cytokine production at 8 h.p.i. with a subsequent rise to baseline 
levels or above at 24 h.p.i. for many secreted factors (Table 3). Increased 
expression of IL-6, IL-1β, IL-10, and IL-18 was noted by 24 h.p.i., which is in 
agreement with other studies in various cell types (103-105). Of note, the 
majority of the cytokines and chemokines were minimally expressed by ex vivo B 
cells. Surprisingly, VACV infection did not significantly affect B cell function, 
measured by cytokine and chemokine production, or activation, suggesting 
VACV was still able to regulate the host response during an abortive infection. 
However, the host cell still responded to the viral infection.    
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Table 3. Functional analysis of ex vivo B cells. 
Analytes 
3 Hours 8 Hours 24 Hours 
uninfected infected uninfected infected uninfected infected 
IFNα 2.3 ± 3.3 2.7 ± 3.6 1.9 ± 1.7 0.7 ± 1.2 2.2 ± 2.6 5.2 ± 5.4 
IFNγ 2.4 ± 1.7 2.4 ± 1.7 2.2 ± 1.5 1.3 ± 0.8 1.8 ± 1.3 2.2 ± 1.1 
IL-1α 1.0 ± 1.1 0.7 ± 0.8 0.5 ± 0.7 0.5 ± 0.5 0.9 ± 0.8 1.5 ± 1.7 
IL-1β 1.5 ± 1.7 3.1 ± 4.5 1.1 ± 1.0 0.9 ± 1.4 1.0 ± 1.8 3.2 ± 3.6 
IL-1RA 108.1 ± 122.8 153.5 ± 296.5 165.1 ± 183.5 49.7 ± 77.8 235.8 ± 331.4 1267 ± 2563 
IL-2 13.8 ± 8.7 11.7 ± 6.5 15.6 ± 11.7 10.6 ± 4.0 10.7 ± 5.2 14.1 ± 9.9 
IL-4 10.5 ± 6.5 10.6 ± 8.5 9.7 ± 6.5 5.9 ± 3.3 9.8 ± 4.3 11.9 ± 6.4 
IL-5 5.6 ± 1.8 6.1 ± 4.8 4.7 ± 2.6 4.3 ± 3.3 4.6 ± 3.3 6.7 ± 4.3 
IL-6 19.5 ± 30.9 35.3 ± 46.7 27.4 ± 31.6 5.9 ± 13.5 16.0 ± 25.6 77.2 ± 109.4 
IL-7 1.7 ± 1.4 2.2 ± 1.3 2.0 ± 1.8 1.0 ± 1.0 1.9 ± 1.4 3.5 ± 2.0 
IL-9 18.4 ± 35.7 10.6 ± 20.2 15.6 ± 25.0 2.0 ± 3.7 8.1 ± 18.6 19.2 ± 24.6 
IL-10 1.0 ± 0.4 1.0 ± 0.2 1.0 ± 0.3 1.1 ± 0.5 1.0 ± 0.2 2.6 ± 1.8 
IL-12p70 0.04 ± 0.0 0.04 ± 0.0 0.04 ± 0.0 0.04 ± 0.0 0.04 ± 0.0 0.3 ± 0.4 
IL-13 5.2 ± 5.6 4.2 ± 4.7 4.3 ± 5.0 1.5 ± 1.6 2.8 ± 3.3 3.6 ± 3.0 
IL-15 8.6 ± 5.6 13.1 ± 14.2 6.9 ± 6.4 5.0 ± 4.2 12.1 ± 5.5 13.7 ± 12.4 
IL-17A 3.4 ± 3.1 4.4 ± 5.0 3.9 ± 2.5 1.7 ± 1.9 3.1 ± 1.8 5.5 ± 4.1 
IL-18 10.5 ± 6.2 15.0 ± 12.6 12.2 ± 10.8 8.5 ± 4.9 11.4 ± 6.5 15.1 ± 10.6 
IL-21 11.5 ± 9.4 23.6 ± 21.5 10.7 ± 10.1 6.4 ± 6.2 17.3 ± 11.2 25.5 ± 27.1 
IL-22 86.4 ± 96.2 50.0 ± 38.8 53.9 ± 37.0 38.2 ± 18.7 42.0 ± 33.5 63.8 ± 49.6 
IL-23 289.9 ± 351.4 235.5 ± 305.3 138.3 ± 129.6 175.9 ± 155.8 439.7 ± 418.6 478.5 ± 470.0 
IL-27 59.4 ± 85.7 73.4 ± 116.3 48.6 ± 67.6 5.1 ± 0.0 28.0 ± 56.1 56.9 ± 70.5 
IL-31 54.6 ± 119.1 27.0 ± 58.0 39.5 ± 63.5 7.5 ± 10.3 3.3 ± 0.0 12.7 ± 23.1 
LIF 0.6 ± 0.4 1.0 ± 0.3 0.7 ± 0.4 0.7 ± 0.4 0.7 ± 0.6 0.9 ± 0.5 
TNFα 7.9 ± 2.9 8.2 ± 3.0 8.0 ± 4.3 6.9 ± 3.8 7.0 ± 2.7 26.0 ± 42.0 
TNFβ 1.6 ± 0.0 1.6 ± 0.0 1.7 ± 0.2 1.6 ± 0.0 1.6 ± 0.0 1.6 ± 0.0 
Eotaxin 1.5 ± 0.2 1.9 ± 0.9 1.6 ± 0.3 1.3 ± 0.3 1.7 ± 0.6 2.2 ± 1.5 
GROα 1.4 ± 1.6 1.0 ± 1.1 0.8 ± 0.6 3.3 ± 3.8 1.3 ± 1.3 16.3 ± 33.4 
IL-8 193.5 ± 344.9 132.1 ± 233.7 356.8 ± 745.8 276.6 ± 327.7 392.1 ± 786.7 988.9 ± 1095 
IP-10 6.6 ± 4.1 7.4 ± 4.1 7.2 ± 4.3 4.6 ± 3.6 5.9 ± 6.5 12.2 ± 12.8 
MCP-1 338.4 ± 424.5 294.7 ± 409.0 307.8 ± 356.2 269.6 ± 357.7 1317± 1469 1262 ± 1533 
MIP-1α 3.6 ± 3.0 3.7 ± 2.3 5.2 ± 6.0 8.8 ± 9.8 5.8 ± 2.9 115.1 ± 258.3 
MIP-1β 23.7 ± 32.4 28.2 ± 29.9 18.8 ± 23.2 35.8 ± 34.0 52.7 ± 17.6 119.9 ± 125.0 
RANTES 6.2 ± 8.9 6.0 ± 7.4 4.9 ± 4.8 3.2 ± 2.7 3.7 ± 3.6 12.1 ± 15.5 
SDF-1α 394.0 ± 528.0 342.8 ± 576.6 197.1 ± 212.8 296.1 ± 392.9 806.0 ± 915.1 809.5 ± 824.5 
BDNF 2.3 ± 2.5 2.5 ± 2.6 2.0 ± 2.0 1.3 ± 0.7 2.1 ± 2.3 4.0 ± 3.7 
EGF 3.6 ± 4.0 3.7 ± 3.9 2.6 ± 1.5 2.1 ± 1.4 3.9 ± 4.3 4.2 ± 3.7 
FGF-2 6.1 ± 8.2 13.7 ± 20.9 7.1 ± 7.2 44.0 ± 87.1 5.3 ± 4.3 26.4 ± 37.0 
GM-CSF 13.1 ± 13.4 16.7 ± 12.3 20.2 ± 22.9 8.6 ± 8.9 9.3 ± 10.2 22.0 ± 12.6 
HGF 8.0 ± 5.7 7.6 ± 5.4 7.0 ± 4.4 10.1 ± 11.0 9.1 ± 4.4 12.6 ± 11.0 
NGFβ 2.5 ± 1.5 4.7 ± 4.8 4.2 ± 2.1 3.2 ± 2.4 2.9 ± 2.1 3.8 ± 3.3 
PDGF-BB 8.4 ± 6.0 10.7 ± 6.7 5.8 ± 1.8 7.6 ± 4.1 7.1 ± 3.7 11.0 ± 4.9 
PIGF-1 3.4 ± 4.4 4.8 ± 7.0 2.2 ± 3.1 2.2 ± 2.5 3.5 ± 3.5 16.1 ± 21.5 
SCF 3.7 ± 3.1 3.2 ± 3.4 2.5 ± 2.9 1.2 ± 0.9 2.5 ± 2.1 3.2 ± 3.2 
VEGF-A 11.9 ± 15.9 15.3 ± 17.6 8.0 ± 10.8 6.8 ± 8.8 10.0 ± 11.5 35.4 ± 38.3 
VEGF-D 2.3 ± 2.4 3.0 ± 2.9 1.6 ± 0.8 2.1 ± 1.7 3.4 ± 3.9 3.9 ± 4.2 
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Complete multiplex analysis of 45 cytokines, chemokines, and growth factors 
from supernatants of unstimulated B cells either incubated with or without VACV-
WR at a MOI of 2. Pooled data from 6 donors.
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Detection of two B cell populations differing in size and complexity via FCM 
 While evaluating VACV binding and infection in ex vivo isolated B cells, 
two populations differing in size and complexity were observed by FCM (Fig. 15). 
Two populations of B cells have been noted previously, but were found by 
density gradient rather than FCM (106). To confirm that both populations were 
indeed live cells, the populations in isolated B cells were assessed by calcein 
AM, which fluoresces in live cells with functional esterases to cleave the small 
molecule. Greater than 95% of both populations, deemed Bsmall (left) and Blarge 
(right), was live and viable cells (Fig. 16). Additionally, the cell cycle phase and 
proliferation were tested. Blarge displayed an increased frequency of cells in the S 
or M phase as compared to Bsmall (Fig. 17a). Moreover, Blarge exhibited an 
increased frequency of Ki-67-positive cells, denoting proliferating cells, as 
compared to Bsmall (Fig. 17b). These data suggest that both Bsmall and Blarge 
populations were comprised of viable cells and similar to that observed 
previously by density gradient (106). 
 Since both populations were viable and there was a difference in the 
proliferative ability, phenotypic analysis of Bsmall and Blarge, both ex vivo and mock 
infected cells, was subsequently completed. When comparing Bsmall and Blarge, 
Blarge displayed an increased frequency of memory B cells, while the remaining B 
cell subsets were consistent between the two populations (Fig. 18a). No 
difference in the prevalence of cells displaying activation markers was observed 
between both populations (Fig. 18b). Blarge exhibited a decrease in the 
percentage of CXCR4-positive cells and an increase in CCR6-positive B cells 
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compared to Bsmall (Fig. 18b). However, the frequency of CXCR5-positive cells 
was equally high in both populations (Fig. 18b). Phenotypic analysis was also 
completed in 12 h.p.i. mock-infected B cells because of the differences in subset 
frequencies in cultured ex vivo total B cells. In 12 h.p.i. mock-infected cells, the 
difference in memory B cell prevalence was still noted, nevertheless there was 
also increased plasma cell percentages in Bsmall (Fig.19a). Additionally, great 
variation in the frequency of chemokine receptor or activation marker positive B 
cells was observed between the two populations. CXCR5 expressing cells 
remained at the same frequency in Bsmall, whereas the frequency increased in 
Blarge (Fig. 19b). An increase in CXCR4-positive cells was noted in both 
populations, but to a greater extent in Blarge (Fig. 19b). These data suggest 
possible activation in both Bsmall and Blarge post-incubation. Additionally, the 
increased percentage of CCR6-positive cells in Blarge remained consistent even 
as the percentage of CCR6-positive cells decreased (Fig. 19b). CXCR5 
expressing cells decreased slightly in Bsmall compared to Blarge (Fig. 19b). Bsmall 
displayed higher CD80-positive cells, while Blarge displayed higher CD86-positive 
cells (Fig. 19b). These data suggest that culturing B cells, even in the absence of 
virus, leads to alterations in cell surface molecule and cell death. 
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Figure 15. Two B cell populations observed in isolated B cells. A) 
Representative FCM depicting two populations in total B cells. B) Pooled data for 
B cell populations. Each dot in a group represents data from a single individual; 
n=5. ns, not significant; Bs, Bsmall B cell population; BL, Blarge B cell population. 
Lines represent mean ± SEM. 
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Figure 16. Bsmall and Blarge populations were both viable. A) Representative 
FCM depicting cell viability staining using calcein AM. B) Pooled data for the two 
B cell population viability. Graphs represent mean ± SEM; n=3. ns, not 
significant; Bs, Bsmall B cell population; BL, Blarge B cell population; MeOH fixed, 
methanol fixed dead cells. 
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Figure 17. Blarge displayed increased proliferation. A) Analysis of cell cycle 
phase by propidium iodide (PI) staining. Each dot in a group represents data 
from a single individual; n=3. B) Evaluation of proliferating cells via Ki-67 staining. 
Each dot in a group represents data from a single individual; n=4. Lines 
represent mean ± SEM. *, p < 0.05. 
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Figure 18. Blarge contained more memory B cells in ex vivo B cells. A) 
Evaluation of specific B cells populations in Bsmall and Blarge using the four B cell 
phenotyping antibody panels from Table 1. Distribution of B cell subsets in ex 
vivo B cell populations. B) Percentage of cells expressing specific surface 
molecules in B cell populations. Graphs represent mean ± SEM; n= 5. ***, p < 
0.001. 
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Figure 19. Bsmall contained more plasma cells in incubated B cells. A) 
Evaluation of specific B cells populations in Bsmall and Blarge incubated for 12 h 
using the four B cell phenotyping antibody panels from Table 1. Distribution of B 
cell subsets in 12 h-incubated B cell populations. B) Percentage of cells 
expressing specific surface molecules in B cell populations. Graphs represent 
mean ± SEM; n= 5. ***, p < 0.001. 
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Differential VACV binding to Bsmall and Blarge 
 To assess if the differences between the two populations affected VACV 
infection, VACV binding to Bsmall and Blarge was first examined via FCM. Although 
Blarge was the minor population in ex vivo B cells, VACV bound to a greater 
percentage of cells in the Blarge population as compared to Bsmall (Fig.20a, 20b). 
However, Bsmall cells did display VACV binding in greater than 40% of the 
population (Fig. 20a, 20b). Since a disparity was observed between Bsmall and 
Blarge VACV binding, we sought to assess VACV binding in specific B cell subsets 
in these populations by FCM. Of note, in both populations, VACV binding 
displayed relatively low binding to plasmablasts, once more suggesting that 
plasmablasts are resistant to VACV binding (Fig. 21a). The remaining B cell 
subsets exhibited differences between the two populations, with Blarge having a 
higher prevalence of VACV-bound cells (Fig. 21a). Additionally, Blarge exhibited 
increased VACV binding to cells expressing activation markers and chemokine 
receptors when compared to Bsmall (Fig. 21b). These data suggest that the cell 
surface molecules on Blarge cells inherently differ from Bsmall cells, which allow for 
increased VACV binding. Additionally, the increase in virus binding in the Blarge 
cells could be due to increased cell surface.  
As expected, examination of B cell populations in VACV-infected cells 
revealed the distribution of the B cell subsets in the VACV-bound cells (Fig. 22a) 
was similar to the distribution seen in the mock-infected Bsmall and Blarge cells (Fig. 
18a). Evaluation of specific activation markers and possible poxvirus receptors in 
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VACV-bound cells revealed results resembling the distribution noted in mock-
infected B cells (Fig. 22b, 18b). 
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Figure 20. Differential VACV binding in Bsmall and Blarge. Analysis of VACV 
binding at a MOI of 0.5 in both Bsmall and Blarge populations. A) Representative 
FCM plots for VACV binding in Bsmall and Blarge. B) Pooled data from eight healthy 
donors. Each dot in a group represents data from a single individual. **, p < 0.01. 
Bs, Bsmall B cell population; BL, Blarge B cell population. 
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Figure 21. Plasmablasts were resistant to VACV binding in both Bsmall and 
Blarge populations. Analysis of VACV binding (vA5L-YFP) at a MOI of 0.5 in both 
B cell populations. A) In the two B cell populations, VACV binding in five major B 
cell subsets found in peripheral blood and three subtypes of memory B cells. B) 
Analysis of VACV binding to cells expressing common activation markers and 
chemokine receptors in both populations. Graphs represent mean ± SEM; n= 5. 
***, p < 0.001. 
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Figure 22. B cell subsets in VACV bound B cells. A) Percentage of cells 
displaying specific B cell phenotypes in the VACV-bound (vA5L-YFP) cells within 
both B cell populations. B) Percentage of cells displaying specific markers in the 
VACV- bound (vA5L-YFP) cells within both populations. Graphs represent mean 
± SEM; n= 5. *, p < 0.05; ***, p < 0.001. 
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Differential VACV infection to Bsmall and Blarge 
As mentioned previously, Blarge exhibited increased memory B cell 
frequency, and memory B cells were preferentially entered and infected by VACV 
in total B cells (Fig.18a, 9b). This suggests that VACV entry and infection in Blarge 
would be increased compared to Bsmall. Assessment of VACV infection in both 
populations demonstrated an increase in VACV-infected cells in Blarge as 
compared to Bsmall (Fig. 23a, 23b). Since VACV displayed an infection disparity 
between Bsmall and Blarge cells, we sought to assess VACV infection in specific B 
cell subsets by FCM. The majority of the B cell subsets exhibited similar 
percentages of VACV-infected cells between Bsmall and Blarge cells, except for 
transitional B cells which had a higher frequency of VACV-infected Blarge cells 
(Fig. 24a). Of the activation markers and chemokine receptors examined, Blarge 
cells displayed higher frequencies of VACV-infected cells when compared to 
Bsmall (Fig. 24b). However, VACV infection was similar between the two 
populations in CD86 expressing cells (Fig. 24b) despite Blarge cells displaying a 
larger percentage of VACV-bound cells (Fig. 21b).  
 Examination of B cell populations in VACV-infected cells revealed 
memory B cells in the Blarge population, specifically IgM only and class-switched 
memory, displayed an increased frequency of VACV-infected cells, whereas 
plasma cells in the Bsmall population revealed an increased frequency of VACV-
infected cells (Fig. 25a). While Bsmall cells had less CD86 and more CD80 
expressing cells, no difference in the percentage of VACV-infected cells was 
noted between the two populations (Fig. 25b). Evaluation of specific chemokine 
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receptors in VACV-infected cells in Bsmall and Blarge cells revealed results 
resembling the distribution noted in mock infected B cells (Fig. 25b).  
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Figure 23. Differential VACV infection in Bsmall and Blarge. Analysis of VACV 
infection (12 h) at a MOI of 0.5 (VV-EGFP) in both B cell populations. A) 
Representative FCM plots for VACV infection in Bsmall and Blarge. B) Pooled data 
from eight healthy donors. Each dot in a group represents data from a single 
individual. **, p < 0.01. Bs, Bsmall B cell population; BL, Blarge B cell population. 
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Figure 24. Transitional B cells displayed increased infection in Blarge cells. 
Analysis of 12 h VACV infection (VV-EGFP) at a MOI of 0.5 in both B cell 
populations. A) In the two B cell populations, VACV infection in five major B cell 
subsets found in peripheral blood and three subtypes of memory B cells. B) 
Analysis of VACV infection in cells expressing common activation markers and 
chemokine receptors in both populations. Graphs represent mean ± SEM; n= 3. 
**, p < 0.01; ***, p < 0.001. 
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Figure 25. B cell subsets in VACV infected B cells. A) Percentage of cells 
displaying specific B cell phenotypes in the VACV-infected cells within both B cell 
populations. B) Percentage of cells displaying specific markers in the VACV- 
infected cells within both populations. Graphs represent mean ± SEM; n= 3. *, p 
< 0.05; ***, p < 0.001. 
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Stimulated B cells displayed productive VACV infection 
 Previous studies have shown that activation of naïve T cells leads to 
susceptibility to VACV binding and infection contrary to VACV binding resistant 
resting T cells (56, 98). Additionally, autoimmune skin disorders are a 
contraindication for receiving the smallpox vaccine and these disorders result in 
overactive B cells (92, 107). Thus, we examined VACV infection in stimulated B 
cells to assess the effect of cell activation on VACV infection in B cells. Cell 
surface marker expression and cytokine production were assessed to first 
confirm B cell activation. Stimulated B cells displayed increased surface 
expression of CD69, a common early lymphocyte activation marker, and CD86, a 
common lymphocyte activation marker, suggesting successful activation (Fig. 
26a). CD83, a B cell activation marker, expression was also increased in the 
stimulated B cells compared to the unstimulated B cells (Fig. 26a). Expression of 
CD80 was slightly upregulated, but to a lesser degree when compared to CD69, 
CD83, and CD86 (Fig. 26a). In addition to cell surface activation markers, the 
cytokines IL-6 and IL-10, which are usually upregulated during activation of B 
cells, were assessed. IL-6 expression was increased in stimulated when 
compared to unstimulated B cells which confirmed the activation of the B cells 
(Fig. 26b). Furthermore, IL-10 expression was also increased in the stimulated B 
cells but was not significant due to the immense variation between samples (Fig. 
26c). Evaluation of multiple other cytokines via multiplex confirmed the drastic 
alterations in cytokine production expected after stimulation (Table 4).  
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To assess the effect of stimulation on VACV infection in B cells, both non-
stimulated and stimulated B cells were infected with VACV. By 24 h.p.i., 
stimulated B cells exhibited greater VACV infection as compared to unstimulated 
cells (Fig. 27). To further examine the effect of stimulation on VACV infection in B 
cells, VACV gene expression was examined by RT-PCR. The viral gene 
expression pattern observed in HeLa cells is early viral gene expression 
occurring within 2 h.p.i., intermediate within 3 to 6 h.p.i., and late genes by 6 to 8 
h.p.i. Assessment of VACV gene expression in infected stimulated B cells 
showed expression of early, intermediate, and late viral gene expression (Fig. 
28). The pattern of viral gene expression in stimulated B cells was similar to that 
observed in the HeLa cell line. Since the viral gene expression was similar to that 
of a cell line with productive VACV infection, we next examined viral replication in 
stimulated B cells. Plaque assays were completed on stimulated B cells infected 
with VACV WR at a MOI of 2 and their supernatants. In stimulated VACV-
infected B cells, viral titers displayed a trend of increasing in the cells over the 48 
hour period (Fig. 289a, 29b). However, viral titers reduced over time in the 
supernatants suggesting new virions were generated but did not undergo egress 
(Fig. 29c, 29d).  
 To better understand the effect of VACV infection in stimulated B cells, we 
evaluated B cell function during VACV infection by examining cytokine production 
via multiplex analysis. When infected cells were compared to uninfected, the 8 
h.p.i. and 24 h.p.i. infected cells displayed a trend of decreased cytokine levels 
(Table 5). Additionally, using 3 h.p.i. as the baseline, there was a trend of steadily 
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increasing cytokine levels in the infected, stimulated B cells in the later time 
points (Table 5). When the cytokine production was narrowed down to several 
cytokines and chemokines involved in viral infection and examined on a single 
donor level, IL-10 and IL-21 displayed patterns amongst the six donors. For the 
majority of the donors, IL-10 levels stayed level at 3 h.p.i. and decreased at 8 
h.p.i. and 24 h.p.i. in infected B cells when compared to uninfected cells (Table 
6). IL-21 displayed a different pattern with increased expression at 3 h.p.i. 
followed by decreased and subsequently increased expression at 8 h.p.i. and 24 
h.p.i., respectively (Table 6). Of note, IFNα levels were decreased or stayed 
relative level over the 24 h of infection, suggesting that VACV infection was 
regulating the immune response as seen previously in other studies (Table 6) 
(108).  
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Figure 26. B cell activation analysis. Evaluation of stimulation in B cells. 
Purified B cells were cultured in the presence of 20 ug/ml AffiniPure F(ab’)2 Goat 
Anti-Human IgG + IgM (H+L) and 50 nM TLR9 agonist CpG ODN 2006 for 24 h. 
A) Analysis of B cell activation by assessing common B cell activation markers 
via FCM. B) IL-6 levels in the supernatant of unstimulated and stimulated B cells. 
n=6. C) IL-10 levels in unstimulated and stimulated B cells. n=5.  unstim, 
unstimulated B cells; stim, stimulated B cells; ns, not significant; h.p.i., hours 
post-infection. Lines represent mean ± SEM. ***, p < 0.001. ns, not significant. 
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Table 4. Cytokine, chemokine, and growth factor production in 
unstimulated and stimulated B cells. 
Analytes 
3 Hours 8 Hours 24 Hours 
unstimulated stimulated unstimulated stimulated unstimulated stimulated 
IFNα 2.3 ± 3.3 19.9 ± 13.7 1.9 ± 1.7 35.8 ± 21.1 2.2 ± 2.6 47.0 ± 54.8 
IFNγ 2.4 ± 1.7 44.0 ± 40.0 2.2 ± 1.5 83.9 ± 71.4 1.8 ± 1.3 79.0 ± 113.4 
IL-1α 1.0 ± 1.1 8.4 ± 5.5 0.5 ± 0.7 11.8 ± 8.4 0.9 ± 0.8 14.2 ± 15.8 
IL-1β 1.5 ± 1.7 38.3 ± 27.2 1.1 ± 1.0 76.4 ± 65.4 1.0 ± 1.8 125.2 ± 169.2 
IL-1RA 108.1 ± 122.8 1761 ± 1369 165.1 ± 183.5 3661 ± 2915 235.8 ± 331.4 36391 ± 82493 
IL-2 13.8 ± 8.7 132.8 ± 86.8 15.6 ± 11.7 230.6 ± 192.5 10.7 ± 5.2 200.8 ± 212.3 
IL-4 10.5 ± 6.5 75.1 ± 45.7 9.7 ± 6.5 142.9 ± 99.1 9.8 ± 4.3 147.0 ± 140.5 
IL-5 5.6 ± 1.8 33.1 ± 19.1 4.7 ± 2.6 47.7 ± 27.7 4.6 ± 3.3 33.9 ± 22.6 
IL-6 19.5 ± 30.9 748 ± 399 27.4 ± 31.6 1738 ± 1261 16.0 ± 25.6 2921 ± 3939 
IL-7 1.7 ± 1.4 12.1 ± 5.9 2.0 ± 1.8 15.7 ± 7.7 1.9 ± 1.4 18.6 ± 8.5 
IL-9 18.4 ± 35.7 18.1 ± 27.4 15.6 ± 25.0 36.8 ± 42.3 8.1 ± 18.6 83.3 ± 121.6 
IL-10 1.0 ± 0.4 32.0 ± 26.2 1.0 ± 0.3 127.8 ± 144.5 1.0 ± 0.2 215.0 ± 146.0 
IL-12p70 0.04 ± 0.0 26.7 ± 18.5 0.04 ± 0.0 38.2 ± 21.5 0.04 ± 0.0 42.3 ± 36.0 
IL-13 5.2 ± 5.6 35.5 ± 19.1 4.3 ± 5.0 53.7 ± 33.1 2.8 ± 3.3 61.8 ± 52.3 
IL-15 8.6 ± 5.6 87.4 ± 37.3 6.9 ± 6.4 136.0 ± 68.9 12.1 ± 5.5 146.6 ± 124.1 
IL-17A 3.4 ± 3.1 50.6 ± 29.8 3.9 ± 2.5 67.4 ± 44.6 3.1 ± 1.8 67.1 ± 61.9 
IL-18 10.5 ± 6.2 54.3 ± 25.5 12.2 ± 10.8 105.5 ± 69.2 11.4 ± 6.5 138.7 ± 183.2 
IL-21 11.5 ± 9.4 458.9 ± 338.7 10.7 ± 10.1 566.2 ± 356.9 17.3 ± 11.2 411.4 ± 340.5 
IL-22 86.4 ± 96.2 95.9 ± 29.4 53.9 ± 37.0 130.6 ± 63.7 42.0 ± 33.5 138.6 ± 51.2 
IL-23 289.9 ± 351.4 334.2 ± 266.4 138.3 ± 129.6 557.2 ± 360.0 439.7 ± 418.6 701.7 ± 529.6 
IL-27 59.4 ± 85.7 545.3 ± 294.9 48.6 ± 67.6 736.1 ± 497.4 28.0 ± 56.1 909.1 ± 909.4 
IL-31 54.6 ± 119.1 57.4 ± 64.3 39.5 ± 63.5 105.8 ± 142.5 3.3 ± 0.0 125.4 ± 138.8 
LIF 0.6 ± 0.4 7.1 ± 3.5 0.7 ± 0.4 9.2 ± 4.4 0.7 ± 0.6 8.5 ± 5.6 
TNFα 7.9 ± 2.9 36.1 ± 22.0 8.0 ± 4.3 73.0 ± 57.6 7.0 ± 2.7 82.0 ± 83.3 
TNFβ 1.6 ± 0.0 1.7 ± 0.2 1.7 ± 0.2 10.4 ± 17.7 1.6 ± 0.0 130.3 ± 226.7 
Eotaxin 1.5 ± 0.2 2.9 ± 1.3 1.6 ± 0.3 5.3 ± 2.7 1.7 ± 0.6 6.4 ± 5.0 
GROα 1.4 ± 1.6 8.3 ± 11.0 0.8 ± 0.6 28.7 ± 39.0 1.3 ± 1.3 67.1 ± 129.2 
IL-8 193.5 ± 344.9 523.8 ± 580.7 356.8 ± 745.8 1339 ± 1058 392.1 ± 786.7 2762 ± 3667 
IP-10 6.6 ± 4.1 8.4 ± 3.2 7.2 ± 4.3 12.0 ± 5.3 5.9 ± 6.5 18.0 ± 9.1 
MCP-1 338.4 ± 424.5 719.3 ± 799.6 307.8 ± 356.2 1409 ± 1415 1317 ± 1469 2191 ± 2807 
MIP-1α 3.6 ± 3.0 65.7 ± 35.5 5.2 ± 6.0 123.1 ± 72.3 5.8 ± 2.9 274.3 ± 414.8 
MIP-1β 23.7 ± 32.4 174.4 ± 54.3 18.8 ± 23.2 393.1 ± 125.4 52.7 ± 17.6 841.3 ± 620.6 
RANTES 6.2 ± 8.9 4.7 ± 3.5 4.9 ± 4.8 16.8 ± 26.0 3.7 ± 3.6 19.7 ± 19.1 
SDF-1α 394.0 ± 528.0 1777 ± 1581 197.1 ± 212.8 3377 ± 2579 806.0 ± 915.1 6279 ± 9814 
BDNF 2.3 ± 2.5 3.5 ± 1.9 2.0 ± 2.0 5.3 ± 2.8 2.1 ± 2.3 8.2 ± 10.8 
EGF 3.6 ± 4.0 8.1 ± 2.6 2.6 ± 1.5 10.7 ± 4.1 3.9 ± 4.3 13.2 ± 9.1 
FGF-2 6.1 ± 8.2 8.7 ± 8.7 7.1 ± 7.2 12.5 ± 14.3 5.3 ± 4.3 14.0 ± 16.4 
GM-CSF 13.1 ± 13.4 168.8 ± 78.1 20.2 ± 22.9 197.3 ± 111.0 9.3 ± 10.2 180.3 ± 126.2 
HGF 8.0 ± 5.7 86.1 ± 46.7 7.0 ± 4.4 127.0 ± 79.8 9.1 ± 4.4 162.3 ± 139.8 
NGFβ 2.5 ± 1.5 20.9 ± 12.7 4.2 ± 2.1 42.8 ± 30.7 2.9 ± 2.1 64.6 ± 88.3 
PDGF-BB 8.4 ± 6.0 13.9 ± 5.4 5.8 ± 1.8 15.9 ± 6.4 7.1 ± 3.7 13.8 ± 5.7 
PIGF-1 3.4 ± 4.4 58.0 ± 35.3 2.2 ± 3.1 93.1 ± 60.1 3.5 ± 3.5 81.2 ± 70.8 
SCF 3.7 ± 3.1 32.6 ± 22.6 2.5 ± 2.9 56.0 ± 41.4 2.5 ± 2.1 62.9 ± 69.4 
VEGF-A 11.9 ± 15.9 470.5 ± 324.9 8.0 ± 10.8 607.0 ± 328.1 10.0 ± 11.5 454.0 ± 266.5 
VEGF-D 2.3 ± 2.4 42.3 ± 20.3 1.6 ± 0.8 47.7 ± 32.1 3.4 ± 3.9 41.2 ± 31.8 
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Cytokine, chemokine, and growth factor multiplex analysis of supernatants from 
unstimulated and stimulated (anti-Human IgG + IgM and CpG ODN 2006 for 24 
h) B cells of six healthy donors.   
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Figure 27. Increased VACV-infected cells in stimulated B cells. Evaluation of 
VACV infection in stimulated B cells using VV-EGFP at a MOI of 2. Each dot in a 
group represents data from a single individual; n=5. *, p < 0.05. h.p.i., hours post-
infection.  
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Figure 28. VACV gene expression occurred in stimulated B cells. VACV 
early (C11R and A23R), intermediate (A2L and G8R), and late (A17L and B7R) 
gene expression in stimulated B cells (anti-Human IgG + IgM and CpG ODN 
2006 for 24 h) assessed by RT-PCR. n=2. 
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Figure 29. VACV infection in stimulated B cells was permissive. A) 
Representative virus plaque assay using stimulated B cells infected with VACV-
WR at a MOI of 2 for various time points after incubation under binding 
conditions. B) Pooled data from plaque assays. Each dot in a group represents 
data from a single individual; n=3. C) Representative plaque assay using 
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stimulated B cell supernatant from B cells infected with VACV-WR at a MOI of 2 
for various time points after incubation under binding conditions. D) Pooled data 
for plaque assays from stimulated B cell supernatants. Each dot in a group 
represents data from a single individual; n=3. Graphs represent mean ± SEM. *, 
p < 0.05. ns, not significant; h.p.i., hours post-infection; PFU, plaque forming unit. 
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Table 5. Functional analysis of stimulated B cells. 
Analytes 
3 Hours 8 Hours 24 Hours 
uninfected infected uninfected infected uninfected infected 
IFNα 19.9 ± 13.7 19.2 ± 12.3 35.8 ± 21.1 26.2 ± 17.4 47.0 ± 54.8 34.3 ± 22.8 
IFNγ 44.0 ± 40.0 42.1 ± 33.8 83.9 ± 71.4 47.3 ± 42.6 79.0 ± 113.4 55.7 ± 65.9 
IL-1α 8.4 ± 5.5 8.5 ± 5.3 11.8 ± 8.4 7.8 ± 7.2 14.2 ± 15.8 13.5 ± 12.2 
IL-1β 38.3 ± 27.2 40.1 ± 32.2 76.4 ± 65.4 54.9 ± 42.7 125.2 ± 169.2 78.2 ± 60.7 
IL-1RA 1761 ± 1369 1609 ± 1064 3661 ± 2915 2286 ± 1984 36391 ± 82493 3407 ± 2218 
IL-2 132.8 ± 86.8 144.4 ± 115.3 230.6 ± 192.5 163.2 ± 120.5 200.8 ± 212.3 201.8 ± 255.1 
IL-4 75.1 ± 45.7 81.3 ± 49.9 142.9 ± 99.1 98.6 ± 64.8 147.0 ± 140.5 122.9 ± 97.3 
IL-5 33.1 ± 19.1 34.4 ± 20.4 47.7 ± 27.7 37.2 ± 22.3 33.9 ± 22.6 49.4 ± 50.9 
IL-6 748.5 ± 399.1 748.9 ± 285.3 1738 ± 1261 1238.0 ± 801.9 2921 ± 3939 3380 ± 2153 
IL-7 12.1 ± 5.9 12.3 ± 6.7 15.7 ± 7.7 13.4 ± 6.1 18.6 ± 8.5 18.6 ± 12.4 
IL-9 18.1 ± 27.4 14.5 ± 21.8 36.8 ± 42.3 15.4 ± 18.5 83.3 ± 121.6 45.6 ± 25.4 
IL-10 32.0 ± 26.2 26.3 ± 15.4 127.8 ± 144.5 77.1 ± 89.3 215.0 ± 146.0 177.0 ± 138.5 
IL-12p70 26.7 ± 18.5 22.6 ± 17.8 38.2 ± 21.5 24.7 ± 18.9 42.3 ± 36.0 34.0 ± 18.6 
IL-13 35.5 ± 19.1 34.8 ± 21.6 53.7 ± 33.1 41.3 ± 29.5 61.8 ± 52.3 53.3 ± 41.3 
IL-15 87.4 ± 37.3 96.8 ± 50.2 136.0 ± 68.9 99.6 ± 57.7 146.6 ± 124.1 124.8 ± 57.0 
IL-17A 50.6 ± 29.8 51.6 ± 30.0 67.4 ± 44.6 50.5 ± 34.7 67.1 ± 61.9 51.6 ± 35.5 
IL-18 54.3 ± 25.5 70.1 ± 42.9 105.5 ± 69.2 66.5 ± 44.5 138.7 ± 183.2 83.7 ± 62.5 
IL-21 458.9 ± 338.7 458.0 ± 279.7 566.2 ± 356.9 404.6 ± 308.0 411.4 ± 340.5 580.8 ± 539.3 
IL-22 95.9 ± 29.4 99.5 ± 33.9 130.6 ± 63.7 99.2 ± 53.8 138.6 ± 51.2 144.9 ± 48.1 
IL-23 334.2 ± 266.4 342.2 ± 312.2 557.2 ± 360.0 414.3 ± 241.5 701.7 ± 529.6 556.9 ± 265.9 
IL-27 545.3 ± 294.9 510.9 ± 299.3 736.1 ± 497.4 586.2 ± 424.2 909.1 ± 909.4 717.5 ± 478.4 
IL-31 57.4 ± 64.3 57.8 ± 72.3 105.8 ± 142.5 52.1 ± 76.5 125.4 ± 138.8 98.8 ± 111.9 
LIF 7.1 ± 3.5 6.9 ± 2.8 9.2 ± 4.4 6.9 ± 3.9 8.5 ± 5.6 7.4 ± 3.5 
TNFα 36.1 ± 22.0 37.4 ± 22.7 73.0 ± 57.6 56.3 ± 36.5 82.0 ± 83.3 73.7 ± 71.6 
TNFβ 1.7 ± 0.2 1.6 ± 0.0 10.4 ± 17.7 6.6 ± 8.3 130.3 ± 226.7 40.8 ± 50.6 
Eotaxin 2.9 ± 1.3 4.0 ± 2.1 5.3 ± 2.7 4.0 ± 2.3 6.4 ± 5.0 4.8 ± 2.1 
GROα 8.3 ± 11.0 8.0 ± 10.2 28.7 ± 39.0 15.8 ± 21.0 67.1 ± 129.2 20.5 ± 22.0 
IL-8 523.8 ± 580.7 474.7 ± 523.7 1339 ± 1058 958.9 ± 728.6 2762 ± 3667 1477 ± 983.0 
IP-10 8.4 ± 3.2 7.9 ± 5.6 12.0 ± 5.3 9.0 ± 3.2 18.0 ± 9.1 14.5 ± 5.4 
MCP-1 719.3 ± 799.6 611.6 ± 749.7 1409 ± 1415 796.5 ± 793.8 2191 ± 2807 1244 ± 940.7 
MIP-1α 65.7 ± 35.5 49.3 ± 30.3 123.1 ± 72.3 95.4 ± 44.8 274.3 ± 414.8 157.3 ± 53.5 
MIP-1β 174.4 ± 54.3 154.0 ± 55.8 393.1 ± 125.4 298.7 ± 183.6 841.3 ± 620.6 648.8 ± 274.8 
RANTES 4.7 ± 3.5 5.7 ± 5.1 16.8 ± 26.0 8.8 ± 7.7 19.7 ± 19.1 14.9 ± 17.2 
SDF-1α 1777 ± 1581 1617 ± 1041 3377 ± 2579 1617 ± 1328 6279 ± 9814 2758 ± 2049 
BDNF 3.5 ± 1.9 4.3 ± 4.0 5.3 ± 2.8 3.1 ± 1.5 8.2 ± 10.8 5.0 ± 2.2 
EGF 8.1 ± 2.6 8.5 ± 3.9 10.7 ± 4.1 8.6 ± 3.8 13.2 ± 9.1 10.2 ± 2.7 
FGF-2 8.7 ± 8.7 15.1 ± 14.7 12.5 ± 14.3 12.4 ± 13.7 14.0 ± 16.4 17.7 ± 13.9 
GM-CSF 168.8 ± 78.1 170.7 ± 93.7 197.3 ± 111.0 176.7 ± 86.2 180.3 ± 126.2 168.4 ± 129.9 
HGF 86.1 ± 46.7 96.8 ± 57.1 127.0 ± 79.8 99.6 ± 69.5 162.3 ± 139.8 118.8 ± 67.9 
NGFβ 20.9 ± 12.7 25.5 ± 16.0 42.8 ± 30.7 33.9 ± 23.4 64.6 ± 88.3 34.6 ± 31.3 
PDGF-BB 13.9 ± 5.4 14.4 ± 4.8 15.9 ± 6.4 12.9 ± 6.0 13.8 ± 5.7 15.5 ± 6.0 
PIGF-1 58.0 ± 35.3 65.4 ± 34.9 93.1 ± 60.1 59.2 ± 47.5 81.2 ± 70.8 88.0 ± 80.7 
SCF 32.6 ± 22.6 30.3 ± 21.2 56.0 ± 41.4 38.2 ± 30.6 62.9 ± 69.4 45.0 ± 40.6 
VEGF-A 470.5 ± 324.9 467.5 ± 227.0 607.0 ± 328.1 424.5 ± 341.0 454.0 ± 266.5 584.0 ± 507.4 
VEGF-D 42.3 ± 20.3 45.2 ± 24.1 47.7 ± 32.1 40.4 ± 31.0 41.2 ± 31.8 33.9 ± 15.1 
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Complete multiplex analysis of cytokines, chemokines, and growth factors in the 
supernatants of stimulated B cells (anti-Human IgG + IgM and CpG ODN 2006 
for 24 h) either incubated with or without VACV. n=6.    
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Table 6. Individualized cytokine production in stimulated B cells. 
GM-CSF 
  D1 D2 D3 D4 D5 D6 
3h 
uninfected 266.98 109.36 67.87 168.32 149.09 251.12 
infected 241.42 120.32 67.87 266.98 73.22 254.32 
8h 
uninfected 380.73 153.01 111.58 83.46 183.1 271.67 
infected 303.66 75.83 88.39 181.28 231.56 179.45 
24h 
uninfected 383.47 128.8 288.59 62.35 111.58 107.11 
infected 156.9 158.82 111.58 50.63 111.58 421.1 
IFNa 
3h 
uninfected 26.89 9.47 4.63 16.54 18.9 42.92 
infected 33.2 14.52 4.5 6.75 30.25 26.25 
8h 
uninfected 70.2 28 14.81 39.27 15.67 46.66 
infected 51.95 7.29 10.02 37.05 33.03 17.57 
24h 
uninfected 157.07 15.96 36.37 15.09 20.1 37.56 
infected 47.92 20.85 18.31 18.31 25.31 74.92 
IL-4 
3h 
uninfected 105.43 44.35 14.89 72.18 68.29 145.21 
infected 108.79 50.9 35.86 139.01 25.03 128.49 
8h 
uninfected 279.14 63.67 48.7 62.9 234.21 168.72 
infected 177.94 16.12 35.16 144.32 137.24 80.87 
24h 
uninfected 426.33 45.79 106.27 76.11 85.69 141.66 
infected 100.42 56.1 87.3 109.63 66.74 317.27 
IL-5 
3h 
uninfected 59.8 20.9 11.82 24.11 28.51 53.47 
infected 50.98 23.03 11.82 54.73 13.75 52.22 
8h 
uninfected 89.12 29.63 21.96 21.96 67.57 55.99 
infected 64.96 15.74 12.78 31.89 62.37 35.34 
24h 
uninfected 59.8 25.19 64.96 13.75 24.11 15.74 
infected 35.34 38.85 21.96 9.93 40.04 150.57 
IL-6 
3h 
uninfected 1358.4 578.34 233.69 689.86 572.2 1058.48 
infected 1238.71 717.04 391.38 808.01 564.02 773.96 
8h 
uninfected 2649.5 1324.55 611.18 640.04 3824.94 1377.87 
infected 1791.81 509.02 484.66 1375.43 2493.15 773.96 
24h 
uninfected *10934.86 968.94 1298.14 1267.13 1122.29 1938.6 
infected 2090.06 4656.07 913.91 2395.44 3265.17 6961.8 
IL-10 
3h 
uninfected 32.04 10.1 5.41 28.37 79.02 36.84 
infected 37.59 10.7 6.23 37.77 42.63 22.58 
8h 
uninfected 79.8 28.56 25.1 66.32 404.71 162.33 
infected 60.84 7.65 12.68 71.63 251.05 58.82 
24h 
uninfected 231.2 41.88 76.78 227.74 263.71 448.76 
infected 52.82 50.54 60.55 316.05 238.22 344.09 
IL-21 
3h 
uninfected 526.18 371.71 96.36 179.1 532.92 1047.3 
infected 873.41 416.37 128.73 564.56 175.4 589.66 
8h 
uninfected 730.03 880.84 232.09 98.02 981.02 475.08 
infected 640.46 175.4 141.05 267.37 918.15 285.33 
24h 
uninfected 578.22 459.72 991.16 104.72 175.4 158.97 
infected 352.86 861.07 201.51 139.28 378.03 1552.18 
Individualized donor data for several cytokines and chemokines from the 
multiplex analysis of stimulated B cells (anti-Human IgG + IgM and CpG ODN 
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2006 for 24 h) either incubated with or without VACV. *, value above maximum 
detection limit.
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Chapter IV – Discussion 
 
Profile of VACV binding and infection in B cells  
 Currently, various viral vaccines and oncolytic cancer vaccines based on 
live poxvirus vectors, such as MVA and ALVAC, are being used in veterinary 
medicine and tested in clinical trials for use in humans (109-112). These poxvirus 
vectors typically display a reduced induction of the immune response compared 
to wildtype strains. Many clinical trials are evaluating the use of VACV vectors, 
such as MVA, as preventative and therapeutic vaccines to target various 
diseases, such as HIV-1, hepatitis B, influenza, malaria, tuberculosis, and 
cancers (113-121). The RV144 clinical trial demonstrated a limited although 
promising protective effect against HIV-1 by using a poxvirus-based HIV-1 
vaccine prime in combination with a HIV-1 envelope boost (110). Additionally, 
clinical trials using a poxvirus-based oncolytic therapy have demonstrated 
promising safety and efficacy in patients with various cancers (111, 112). The 
interest in poxvirus biology has been renewed due to these successes in 
poxvirus-based vaccines. Discovering VACV receptors and characterizing VACV 
binding and infection tropism will aid in better understanding the distinctive 
VACV-based efficacy, development of more specific and potent oncolytic 
poxvirus-based therapies, and development of more efficacious and safer VACV-
based vaccines against smallpox and other infectious viruses.     
 In the present study, we systematically studied VACV binding to and 
infection of unstimulated ex vivo and stimulated primary human B cells. We 
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observed that VACV bound to primary ex vivo B cells robustly but weakly 
infected these cells (Fig. 4), which is in agreement with previous reports using 
PBMCs (56, 60, 98). Further examination into the binding and infection in these B 
cells showed three patterns of virus binding and infections in the various B cell 
subsets (Fig. 5b, 9b). Our study revealed that only one B cell subset, 
plasmablasts, displayed resistance to VACV binding, while the other subsets 
displayed similar viral binding to each other and other APCs (Fig. 5b). 
Additionally, the majority of the memory B cells with VACV bound displayed viral 
entry and infection, whereas the other subsets were more resistant to viral entry 
and infection despite the high rates of binding (Fig. 5b, 9b). These results 
suggest that most B cell subsets express the receptor(s) necessary for either 
non-specific or specific binding of VACV. However, the greater part of B cells 
appears to lack the cellular signaling pathways necessary for viral uptake and 
entry, and memory B cells may possess these essential viral entry signaling 
pathways and other cellular pathways crucial for other downstream viral events. 
Additionally, these results may indicate that plasmablasts might lack high 
expression of glycoprotein attachment factors necessary for the initial encounter 
between host cell and VACV, as well as the specific receptor(s) necessary for 
viral entry. Although many viruses such as influenza A or hepatitis A use a single 
molecular species as their receptors (25), VACV may require multiple molecular 
species as receptors and only certain subsets of B cells, such as memory B cells, 
express the obligatory receptors for both binding and entry. The drastic 
difference in VACV binding between plasmablasts and the other B cells subsets 
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along with the three binding and infection patterns observed among the B cell 
subsets indicate the various B cell subsets could be an invaluable tool to 
examine the molecular mechanisms involved in VACV binding, penetration, and 
entry potentially, leading to a better understanding of poxvirus tropism and 
binding receptor(s) as well as efficacy of VACV-based smallpox vaccines.  
 Differences in permissivity of infection between ex vivo and stimulated B 
cells were observed in this study. Of note, stimulated B cells displayed higher 
levels of infection when compared to unstimulated cells (Fig. 27). Stimulated B 
cells also exhibited a trend of increasing viral titers over a two-day period, 
suggesting viral replication (Fig. 29a). These data imply stimulation of B cells 
might lead to synthesis of the receptor(s) necessary for viral binding and entry 
and essential changes in signaling pathways to permit viral entry signaling and 
viral replication. Stimulation or activation of B cells leads to changes in 
endocytosis. Activated B cells endocytose various lipid rafts to internalize B cell 
receptors that translocate to lipid rafts (122). Additionally, VACV has been shown 
to localize to receptors in lipid rafts (61).Thus, the higher rate of VACV infection 
noted in stimulated B cells (Fig. 27) may be related to the changes in endocytosis 
upon activation of B cells leading to increased endocytosis of VACV. The use of 
unstimulated and stimulated B cells may also prove to be a valuable model to 
assess the downstream viral events possibly affecting poxvirus tropism.
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Permissivity of VACV infection in ex vivo and stimulated B cells 
In the past, orthopoxvirus infection in humans focused on keratinocytes, 
fibroblasts, epithelial cells, and macrophages depending on the route of infection, 
such as respiratory or dermal. However, animal studies have shown that other 
cell types, including T and B cells, could be important to orthopoxvirus infection. 
A tail scarification mouse study using VACV showed T and B cells were required 
for the anti-viral immune response to provide inoculation site infection control and 
prevention of viral dissemination, respectively (123). Additionally, an assessment 
of immune cell infiltration in rabbits with VACV keratitis revealed infiltration of T 
and B cells into the eye after a corneal VACV inoculation (124). VACV infection is 
permissive in dermal cells and macrophages, and resting T cells are resistant to 
infection (56, 61). Also, activated T cells were shown to be permissive to VACV 
infection (56, 61). However, VACV infection in B cells has not been definitively 
shown. B cell were shown to express low levels of the VACV late gene A56R via 
a reporter virus, implying infection was abortive (56). We have validated abortive 
infection in B cells by showing no virus production in primary B cells using virus 
plaque assays and minimal viral late gene expression (Fig. 11, 14). In contrast, 
we found that upon stimulation, B cells displayed increased VACV infection in 
stimulated compared to unstimulated (Fig. 27) and VACV infection was no longer 
abortive (Fig. 29).  
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VACV infection in memory B cells 
 Memory B cells are crucial for the Ab response to be recalled upon 
recognition of a previously encountered specific Ag and replenishing the plasma 
cell pool. These memory cells are essential for long-term immunity against 
pathogens and developed by vaccination. The smallpox vaccine demonstrates a 
respectable safety profile and leads to the generation of memory B cells to 
provide a long-term immunity (86). VACV displayed robust binding, 65.4%, to 
memory B cells (Fig. 5b). Interestingly, VACV showed a bias towards infecting 
memory B cells, infecting over 50% of memory B cells, when compared to the 
other subsets, which less than 20% were infected (Fig. 9b). Furthermore, class-
switched memory B cells were the predominate memory B cells subtype 
observed in the VACV-infected cells (Fig. 10a). Additionally, Blarge B cells showed 
increased VACV infection and percentage of memory B cells (Fig. 18a, 19a, 
21a). These data suggest that memory B cells are more likely to be infected by 
VACV, when compared to other B cell subsets. An implication of VACV infecting 
memory B cells is the possibility of VACV infection affecting memory B cell 
function and even immunity. Thus, the smallpox vaccine could affect immunity to 
other antigens or pathogens depending on the reaction to the vaccination, such 
as generalized vaccinia or progressive.  
 
VACV infection in relation to proliferation 
Viral infection of a cell usually triggers cell death, but viruses have 
numerous mechanisms to inhibit the viral-induced apoptosis (125). These cellular 
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death subversion mechanisms include producing homologues of anti-apoptotic 
factors (126) or inhibitors of pro-apoptotic factors (127). By inhibiting apoptosis, 
the survival of the cell usually permits viral replication. However, these factors 
are not produced shortly after VACV infection (128). To subvert the induced 
apoptosis early in infection, VACV produces an epidermal growth factor (EGF)-
like growth factor to activate the EGF receptor (EGFR)-Ras pathway required for 
viral replication (129) and act as a mitogen to prime nearby cells for infection 
(130). Additionally, VACV is thought to infect proliferating cells.  
  In total B cells, we observed two populations differing in size and 
complexity, and Blarge displayed an increased percentage of VACV-infected cells 
(Fig. 23). Interestingly, these populations varied in the cell cycle phase and 
proliferative state, with Blarge cells having a higher percentage of proliferating cells 
(Fig. 17). These data suggest Blarge cells may express increased levels of EGFR 
to support VACV infection. Another possibility for the increased VACV infection is 
that Blarge cells are primed, due to their proliferative state, for infection. 
Additionally, the alterations associated with B cell stimulated permitted VACV 
infection and replication when compared to non-permissive ex vivo B cells (Fig. 
29), suggesting that stimulation of B cells support VACV infection possibly 
through EGFR signaling or production of viral factors necessary for evasion of 
apoptosis. 
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Chapter V – Future Directions 
 
Detection of potential VACV receptor(s) 
 No specific poxvirus receptor has been discovered despite the well 
documented preference of the virus for infection of specific primary cells and the 
VACV binding tropism. Identification of the poxvirus binding receptor(s) would 
lead to better engineering strategies for poxvirus-based infectious disease and 
cancer therapies. Additionally, treatments for VACV infection include vaccinia 
immune globulin (VIG) and anti-viral drugs like cidofovir, but anti-viral drugs are 
the only treatment available for orthopoxvirus infections. The development of 
better poxvirus specific anti-viral therapies to treat infections in both the general 
public and vulnerable groups, such as immunocompromised individuals, would 
be assisted by the discovery of the poxvirus receptor(s) for viral binding. 
 This study revealed B cell subsets could be used to assess VACV 
receptors due to the differential binding to specific subsets. Furthermore, our lab 
has demonstrated enrichment of putative VACV receptors in detergent-resistant 
membranes (DRMs) from primary human leukocytes (61). The results from these 
studies from our group (61) reveal that analyzing the DRM fractions from 
plasmablasts compared to plasma or memory B cells would be a method for 
identifying potential VACV binding receptor(s). These B cell subsets provide a 
comparison between a more binding-resistant subset and binding-sensitive 
subsets. Additionally, comparing the non-bound and virus bound plasmablasts 
would permit further narrowing of potential receptor molecules.  
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 DRMs are typically isolated via detergent solutions, either non-ionic or 
ionic. Non-ionic detergent solutions allow for DRM isolation with potential loss of 
some associated proteins, whereas ionic detergents permit isolation and 
preserves the associated proteins. However, detergent-free isolation of DRMs is 
best in preparation for mass spectrometry to prevent anomalies or false-positives 
and support optimal lipid raft characterization. Thus, a detergent-free method 
would need to be employed (131). Proteome analysis of the isolated DRMs 
would require delipidation followed by liquid chromatography mass spectrometry 
(132). These new findings and developed protocols may support the discovering 
of the previously elusive VACV binding receptors. 
 
Analysis of VACV entry and infection in primary human B cell subsets 
 Viral entry is one of the main events restricting VACV infection in primary 
cells. In addition to identifying the VACV binding receptor(s), understanding viral 
entry will support the development of a safer smallpox vaccine and improved 
infectious disease and cancer vaccines. As memory B cells and to a lesser 
extent transitional B cells displayed significant percentages of VACV infected 
cells along with strong binding, viral entry appears to be affected. VACV entry 
and uncoating between the B cell subsets can be assessed to examine defects in 
uncoating. The same confocal assessment used to visualize VACV binding and 
entry can be used to examine any defects in entry and uncoating in various 
sorted B cell subsets. Using the vA5L-YFP reporter virus with staining for an IMV 
membrane protein at different times post-infection, visualization of single-color 
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events would represent virus entry and potential uncoating. Double color signals 
would indicate extracellular virions because the cell membrane would not have 
been permeabilized. To further confirm uncoating, another condition would 
require membrane permeabilization and viral membrane staining to show a lack 
of membrane on the internalized virions. 
 Early and intermediate gene expression was demonstrated to have 
occurred in total B cells. With the variable viral infection among the subsets, viral 
expression would also be assessed by RT-PCR in the subsets to better define to 
subsets contributing to the results seen in total B cells. Since memory B cells 
were the main B cell type noted in the VACV-infected population, VACV infection 
in these cells mostly likely halts before viral late gene transcription. However, this 
does not rule out a minor population contributing to the minimal late gene 
expression seen. Isolated memory B cells would most likely be the B cell subset 
to use for examining the exact mechanism behind the lack of late gene 
expression. This could be assessed by Western blotting for the subunits of the 
vaccinia late transcription factor (VLTF). Additionally, ChIP-seq could be 
implemented to examine the association of this viral transcription factor with the 
viral DNA if the Western blotting shows the presence of VLTF. 
  
Analysis of the antiviral response and cell survival  
 The antiviral response is a key defense against viral infections, and the 
interferon (IFN) response is one of these antiviral responses. The production of 
IFN is initiated by pattern recognition receptors (PRRs) sensing pathogen-
 101 
associated molecular patterns (PAMPs). One PRR of note is cyclic GMP-AMP 
Synthase (cGAS), which senses cytosolic DNA. cGAS activates stimulator of 
interferon genes (STING) which translocates perinuclear to induce interferon 
regulatory factor 3 (IRF-3) (133, 134). Activation of IRF-3 induces IFNβ 
production, a Type I IFN, to combat the viral infection. The Western Reserve 
strain of VACV has been shown to inhibit the IFN response by preventing 
dimerization of STING and subsequent activation of IRF-3 (134). VACV infection 
in unstimulated cells resulted in an abortive infection (Fig. 14) and a slight 
increase in IFNα production, another Type I IFN (Table 3). These data suggest 
that VACV may not be inhibiting the IFN response and thus leading to an 
abortive infection. To assess if the antiviral response is activated, IFNβ levels 
would be measured via ELISA. Additionally, phosphorylated STING and IRF-3 
would be evaluated by western blot.  
 Fowlpox virus and VACV have been shown to either encode a Bcl-2 
homologue, an anti-apoptotic factor or increase the expression of Bcl-2, 
respectively, in human cells (135, 136). This increase in Bcl-2 leads to an 
inhibition of apoptosis and promotes cell survival. To examine whether apoptosis 
or cell survival are crucial to permissive VACV infection, Bcl-2 expression, along 
with expression of the proapoptotic factor Bax, would be measured via FCM and 
Western blot at various times of VACV infection in both unstimulated and 
stimulated B cells.
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Further analysis of B cell function during VACV infection 
 Studies in cell lines have demonstrated altered cell function during VACV 
infection (63, 105). B cell function was assessed in this study by examining 
cytokine production; however, cytokine production should be measured in more 
than six samples as we observed great variation between the samples leading to 
no significant differences. In addition to cytokine production, B cells have various 
other functions, such as antibody production and antigen presentation. The effect 
of VACV infection on antibody production can be examined in couple of ways. 
One method would be to infect B cells and shortly after stimulation with a known 
Ag, such UV inactivated hepatitis B, to induce antibody production and measure 
antibody levels via ELISA. Another method would be to infect B cells and 
stimulate with CpG or IgM crosslinking to activate the cells, and then measure 
antibody levels. Antigen presentation is easily studied in vitro by using cell lines; 
however, using primary cells for antigen presentation is quite difficult. Thus, 
studying cytokine production and antibody response should be sufficient to 
assess B cell function.  
 To further define the effect of VACV infection on B cell cytokine and 
chemokine production, VACV-infected B cells would first be sorted by phenotype. 
The sorted cells would then undergo single-cell multiplexed cytokine profiling. 
These data would provide a detailed representation of the cytokines produced by 
specific B cell phenotypes infected with the virus and the changes brought on by 
viral infection. 
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Stimulated B cells and eczema vaccinatum 
 While the smallpox vaccination can lead to various adverse events, one of 
the more severe reactions is eczema vaccinatum (EV) which occurs when 
individuals with eczema or atopic dermatitis receive the vaccine. EV is a 
potentially lethal widespread rash with skin lesions caused by viremia. This 
reaction can be successfully treated with VIG or cidofovir. Although having 
eczema is a contraindication to receiving the vaccine, greater than 15% percent 
of the US population has eczema or eczema-like symptoms (91), and individuals 
may not be aware their symptoms are related to eczema. Additionally, individuals 
with eczema could be exposed by a recently vaccinated person with viral 
shedding, which has occurred in the past (137). Despite EV being treatable, the 
underlying mechanisms of this widespread viral dissemination is unknown. The 
skin of individuals with atopic dermatitis have been shown to have defects in the 
epidermal barrier (138) and anti-microbial peptide production (139). These skin 
defects support increased VACV replication which may contribute to the 
widespread lesions. Additionally, immune cells, particularly macrophages, have 
been implicated in contributing to EV (140).  
 Macrophages are not the only immune cell type affected by atopic 
dermatitis or eczema. Among other alterations in the immune system, these 
individuals have significantly higher frequencies of chronically activated memory 
B cells (92). These activated memory B cells could be generating more virions 
along with possibly disseminating the virus to other sites. B cells isolated from 
individuals with these autoimmune skin disorders could be used to examine the 
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role of B cells in EV. First, VACV infection in disease-affected B cells should be 
assessed by flow cytometry and then plaque assays to observe the rate of 
infection as well as the amount of virus production. Transmission of virus could 
be analyzed by co-culturing VACV infected B cells with PBMCs from the same 
donor or a VACV permissive cell line for various amounts of time up to six hours, 
to prevent new virion generation. Additionally, VACV infection could be examined 
in B cells from individuals with EV. EV-patient B cells could be lysed and used for 
plaque assays to assess viral replication or PCR or intracellular VACV core 
staining to analyze the VACV burden in these cells.   
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